Cover Page
Cover Page - shares | 9 Months Ended | |
Sep. 30, 2023 | Nov. 06, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-36847 | |
Entity Registrant Name | Invitae Corporation | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 27-1701898 | |
Entity Address, Address Line One | 1400 16th Street | |
Entity Address, City or Town | San Francisco | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94103 | |
City Area Code | 415 | |
Local Phone Number | 374-7782 | |
Title of 12(b) Security | Common Stock, $0.0001 par value per share | |
Trading Symbol | NVTA | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 286,492,840 | |
Entity Central Index Key | 0001501134 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q3 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 158,007 | $ 257,489 |
Marketable securities | 96,566 | 289,611 |
Accounts receivable | 82,507 | 96,148 |
Inventory | 21,627 | 30,386 |
Prepaid expenses and other current assets | 19,692 | 19,496 |
Total current assets | 378,399 | 693,130 |
Property and equipment, net | 65,446 | 108,723 |
Operating lease assets | 61,639 | 106,563 |
Restricted cash | 10,100 | 10,030 |
Intangible assets, net | 0 | 1,012,549 |
Other assets | 19,531 | 23,121 |
Total assets | 535,115 | 1,954,116 |
Current liabilities: | ||
Accounts payable | 25,185 | 13,984 |
Accrued liabilities | 84,729 | 74,388 |
Operating lease obligations | 17,650 | 14,600 |
Finance lease obligations | 3,948 | 5,121 |
Total current liabilities | 158,419 | 108,093 |
Operating lease obligations, net of current portion | 134,945 | 134,386 |
Finance lease obligations, net of current portion | 855 | 3,780 |
Convertible senior notes, net current portion | 26,907 | 0 |
Debt | 0 | 122,333 |
Convertible senior notes, net | 1,127,830 | 1,470,783 |
Convertible senior secured notes (at fair value) | 196,244 | 0 |
Deferred tax liability | 0 | 8,130 |
Other long-term liabilities | 226 | 4,775 |
Total liabilities | 1,618,519 | 1,852,280 |
Commitments and contingencies | ||
Stockholders’ (deficit) equity: | ||
Common stock | 29 | 25 |
Accumulated other comprehensive income (loss) | 25,378 | (80) |
Additional paid-in capital | 5,061,131 | 4,931,032 |
Accumulated deficit | (6,169,942) | (4,829,141) |
Total stockholders’ (deficit) equity | (1,083,404) | 101,836 |
Total liabilities and stockholders’ (deficit) equity | $ 535,115 | $ 1,954,116 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Revenue: | ||||
Total revenue | $ 121,241 | $ 133,536 | $ 359,129 | $ 393,849 |
Operating expenses: | ||||
Cost of revenue | 82,186 | 116,956 | 258,102 | 324,412 |
Research and development | 58,336 | 87,177 | 184,138 | 330,559 |
Selling and marketing | 37,999 | 49,193 | 127,241 | 172,086 |
General and administrative | 45,619 | 44,939 | 160,826 | 147,221 |
Goodwill and IPR&D impairment | 0 | 0 | 0 | 2,313,047 |
Restructuring, impairment and other costs | 877,289 | 125,222 | 1,010,843 | 130,039 |
Total operating expenses | 1,101,429 | 423,487 | 1,741,150 | 3,417,364 |
Loss from operations | (980,188) | (289,951) | (1,382,021) | (3,023,515) |
Other income (expense), net: | ||||
Gain (loss) on extinguishment of debt, net | 229 | 0 | (10,593) | 0 |
Debt issuance costs | (845) | 0 | (20,704) | 0 |
Change in fair value of convertible senior secured notes | 33,463 | 0 | 72,386 | 0 |
Change in fair value of acquisition-related liabilities | 70 | (527) | 337 | 15,666 |
Other income, net | 4,843 | 2,399 | 15,105 | 3,971 |
Total other income, net | 37,760 | 1,872 | 56,531 | 19,637 |
Interest expense | (5,850) | (14,145) | (23,366) | (42,149) |
Net loss before taxes | (948,278) | (302,224) | (1,348,856) | (3,046,027) |
Income tax benefit | 6,171 | 1,068 | 8,055 | 39,551 |
Net loss | $ (942,107) | $ (301,156) | $ (1,340,801) | $ (3,006,476) |
Net (loss) income per share, basic (in dollars per share) | $ (3.42) | $ (1.27) | $ (5.09) | $ (12.91) |
Net (loss) income per share, diluted (in dollars per share) | $ (3.42) | $ (1.27) | $ (5.09) | $ (12.91) |
Shares used in computing net loss per share, basic | 275,604 | 237,974 | 263,210 | 232,889 |
Shares used in computing net loss per share, diluted | 275,604 | 237,974 | 263,210 | 232,889 |
Test revenue | ||||
Revenue: | ||||
Total revenue | $ 117,561 | $ 128,839 | $ 346,127 | $ 381,518 |
Other revenue | ||||
Revenue: | ||||
Total revenue | $ 3,680 | $ 4,697 | $ 13,002 | $ 12,331 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Net loss | $ (942,107) | $ (301,156) | $ (1,340,801) | $ (3,006,476) |
Other comprehensive (loss) income: | ||||
Unrealized (loss) income on available-for-sale marketable securities, net of tax | (61) | 436 | 92 | (891) |
Changes in fair value attributable to instrument-specific credit risk of convertible senior secured notes measured at fair value, net of tax | 16,529 | 0 | 25,366 | 0 |
Comprehensive loss | $ (925,639) | $ (300,720) | $ (1,315,343) | $ (3,007,367) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) $ in Thousands | Total | Common stock: | Accumulated other comprehensive income (loss): | Additional paid-in capital: | Accumulated deficit: |
Balance, beginning of period at Dec. 31, 2021 | $ 23 | $ (7) | $ 4,701,230 | $ (1,722,848) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Common stock issued | 1 | 9,658 | |||
Unrealized (loss) income on available-for-sale marketable securities, net of tax | $ (891) | (891) | |||
Changes in fair value attributable to instrument-specific credit risk of convertible senior secured notes measured at fair value, net of tax | 0 | 0 | |||
Common stock issued in connection with the exchange of convertible senior notes due 2024 | 0 | ||||
Common stock issued on exercise of stock options, net | 630 | ||||
Common stock issued pursuant to employee stock purchase plan | 5,637 | ||||
Common stock and equity awards issued pursuant to acquisitions | 9,253 | ||||
Stock-based compensation expense | 162,656 | ||||
Net loss | (3,006,476) | (3,006,476) | |||
Balance, end of period at Sep. 30, 2022 | 158,866 | 24 | (898) | 4,889,064 | (4,729,324) |
Balance, beginning of period at Dec. 31, 2021 | 23 | (7) | 4,701,230 | (1,722,848) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Net loss | (3,100,000) | ||||
Balance, end of period at Dec. 31, 2022 | 101,836 | 25 | (80) | 4,931,032 | (4,829,141) |
Balance, beginning of period at Jun. 30, 2022 | 24 | (1,334) | 4,815,383 | (4,428,168) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Common stock issued | 0 | 9,658 | |||
Unrealized (loss) income on available-for-sale marketable securities, net of tax | 436 | 436 | |||
Changes in fair value attributable to instrument-specific credit risk of convertible senior secured notes measured at fair value, net of tax | 0 | 0 | |||
Common stock issued in connection with the exchange of convertible senior notes due 2024 | 0 | ||||
Common stock issued on exercise of stock options, net | 33 | ||||
Common stock issued pursuant to employee stock purchase plan | 0 | ||||
Common stock and equity awards issued pursuant to acquisitions | 3,984 | ||||
Stock-based compensation expense | 60,006 | ||||
Net loss | (301,156) | (301,156) | |||
Balance, end of period at Sep. 30, 2022 | 158,866 | 24 | (898) | 4,889,064 | (4,729,324) |
Balance, beginning of period at Dec. 31, 2022 | 101,836 | 25 | (80) | 4,931,032 | (4,829,141) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Common stock issued | 4 | (55) | |||
Unrealized (loss) income on available-for-sale marketable securities, net of tax | 92 | 92 | |||
Changes in fair value attributable to instrument-specific credit risk of convertible senior secured notes measured at fair value, net of tax | 25,366 | 25,366 | |||
Common stock issued in connection with the exchange of convertible senior notes due 2024 | 40,229 | ||||
Common stock issued on exercise of stock options, net | 1 | ||||
Common stock issued pursuant to employee stock purchase plan | 2,168 | ||||
Common stock and equity awards issued pursuant to acquisitions | 2,202 | ||||
Stock-based compensation expense | 85,554 | ||||
Net loss | (1,340,801) | (1,340,801) | |||
Balance, end of period at Sep. 30, 2023 | (1,083,404) | 29 | 25,378 | 5,061,131 | (6,169,942) |
Balance, beginning of period at Jun. 30, 2023 | 27 | 8,910 | 5,018,112 | (5,227,835) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Common stock issued | 2 | (55) | |||
Unrealized (loss) income on available-for-sale marketable securities, net of tax | (61) | (61) | |||
Changes in fair value attributable to instrument-specific credit risk of convertible senior secured notes measured at fair value, net of tax | 16,529 | 16,529 | |||
Common stock issued in connection with the exchange of convertible senior notes due 2024 | 16,768 | ||||
Common stock issued on exercise of stock options, net | 0 | ||||
Common stock issued pursuant to employee stock purchase plan | 0 | ||||
Common stock and equity awards issued pursuant to acquisitions | 309 | ||||
Stock-based compensation expense | 25,997 | ||||
Net loss | (942,107) | (942,107) | |||
Balance, end of period at Sep. 30, 2023 | $ (1,083,404) | $ 29 | $ 25,378 | $ 5,061,131 | $ (6,169,942) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Cash flows from operating activities: | ||
Net loss | $ (1,340,801) | $ (3,006,476) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Goodwill and IPR&D impairment | 0 | 2,313,047 |
Impairments and losses on disposals of long-lived assets, net | 1,012,360 | 60,317 |
Depreciation and amortization | 100,403 | 104,726 |
Stock-based compensation | 85,554 | 164,314 |
Amortization of debt discount and issuance costs | 5,483 | 11,676 |
Loss on extinguishment of debt, net | 10,593 | 0 |
Debt issuance costs | 20,704 | 0 |
Change in fair value of convertible senior secured notes | (72,386) | 0 |
Remeasurements of liabilities associated with business combinations | (337) | (15,666) |
Benefit from income taxes | (8,055) | (39,551) |
Post-combination expense for acceleration of unvested equity and deferred stock compensation | 1,789 | 4,980 |
Amortization of premiums and discounts on investment securities | (6,259) | 603 |
Non-cash lease expense | 9,309 | 6,832 |
Other | 2,211 | (1,314) |
Changes in operating assets and liabilities, net of businesses acquired: | ||
Accounts receivable | 13,641 | (22,903) |
Inventory | 8,759 | 3,614 |
Prepaid expenses and other current assets | (196) | 9,012 |
Other assets | (139) | 2,740 |
Accounts payable | 8,135 | (6,345) |
Accrued expenses and other long-term liabilities | (6,966) | (540) |
Net cash used in operating activities | (156,198) | (410,934) |
Cash flows from investing activities: | ||
Purchases of marketable securities | (231,044) | (789,622) |
Proceeds from maturities of marketable securities | 430,440 | 541,313 |
Purchases of property and equipment | (4,669) | (48,385) |
Proceeds from sale of property and equipment | 332 | 0 |
Net cash provided by (used in) investing activities | 195,059 | (296,694) |
Cash flows from financing activities: | ||
(Loss) proceeds from public offerings of common stock, net of issuance costs | (55) | 9,658 |
Proceeds from issuance of common stock, net | 2,170 | 6,267 |
Proceeds from issuance of Series B convertible senior secured notes due 2028 | 30,001 | 0 |
Payments for debt issuance costs and prepayment fees | (25,974) | 0 |
Repayment of debt | (135,000) | 0 |
Finance lease principal payments | (3,886) | (4,184) |
Settlement of acquisition obligations | (5,529) | (10,582) |
Net cash (used in) provided by financing activities | (138,273) | 1,159 |
Net decrease in cash, cash equivalents and restricted cash | (99,412) | (706,469) |
Cash, cash equivalents and restricted cash at beginning of period | 267,519 | 933,525 |
Cash, cash equivalents and restricted cash at end of period | 168,107 | 227,056 |
Supplemental cash flow information of non-cash investing and financing activities: | ||
Equipment acquired through finance leases | 0 | 4,472 |
Purchases of property and equipment in accounts payable and accrued liabilities | 764 | 2,531 |
Common stock issued for settlement of hold-back liabilities | 413 | 4,274 |
Exchange of convertible senior notes due 2024 | (320,039) | 0 |
Exchange for convertible senior secured notes due 2028 | 301,171 | 0 |
Operating lease assets obtained in exchange for lease obligations, net | $ 0 | $ 4,495 |
Organization and description of
Organization and description of business | 9 Months Ended |
Sep. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and description of business | 1. Organization and description of business Invitae Corporation ("Invitae," “the Company," "we," "us," and "our") was incorporated in the State of Delaware on January 13, 2010, as Locus Development, Inc. and we changed our name to Invitae Corporation in 2012. We offer high-quality, comprehensive, affordable genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, and rare diseases. Invitae operates in one segment. Strategic realignment On July 18, 2022, the Company initiated a strategic realignment of our operations and began implementing cost reduction programs, which was approved by the board of directors of the Company on July 16, 2022. See Note 10, "Restructuring, impairment and other costs" for additional information regarding our strategic realignment. Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (including normal recurring adjustments) considered necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022. The results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results expected for the full fiscal year or any other periods. Liquidity and Going Concern The accompanying condensed consolidated financial statements have been prepared using the going concern basis of accounting, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business and does not include any adjustments relating to the recoverability and classification of recorded asset and liability amounts that might result from the outcome of the uncertainties described below. Pursuant to Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements — Going Concern (“ASC 205-40”) , management must evaluate whether there are conditions and events, considered in aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these condensed consolidated financial statements are issued. In accordance with ASC 205-40, management’s analysis can only include the potential mitigating impact of management’s plans that have not been fully implemented as of the issuance date if (a) it is probable that management’s plans will be effectively implemented on a timely basis, and (b) it is probable that the plans, when implemented, will alleviate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern. The Company has generally incurred net losses since its inception and had an accumulated deficit of $6.2 billion and $4.8 billion as of September 30, 2023 and December 31, 2022, respectively. The Company had net losses of $3.1 billion, $379.0 million and $602.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. The Company used net cash in operating activities of $493.0 million, $559.8 million and $298.5 million during the years ended December 31, 2022, 2021 and 2020, respectively. The Company had net losses of $942.1 million and $301.2 million for the three months ended September 30, 2023 and 2022, respectively, and $1.3 billion and $3.0 billion for the nine months ended September 30, 2023 and 2022, respectively. Included in the Company's net loss for the three months ended September 30, 2023 are non-cash items such as $881.2 million for impairments and losses on disposals of long-lived assets, net. Included in the Company's net loss for the three months ended September 30, 2022 are non-cash items such as $55.5 million for impairments and losses on disposals of long-lived assets, net. Included in the Company’s net loss for the nine months ended September 30, 2023 are non-cash items such as $1.0 billion for impairments and losses on disposals of long-lived assets, net. Included in the Company’s net loss for the nine months ended September 30, 2022 are non-cash items such as a $2.3 billion loss on impairment of goodwill and in-process research and development (“IPR&D”) intangible asset and $60.3 million related to impairments and losses on disposals of long-lived assets, net. See Note 4, “Intangible assets, net” for additional information. The Company used net cash in operating activities of $156.2 million and $410.9 million for the nine months ended September 30, 2023 and 2022, respectively. At September 30, 2023 and December 31, 2022, the Company had $254.6 million and $547.1 million, respectively, of cash, cash equivalents, and marketable securities. The Company expects to incur additional operating losses and negative operating cash flows in the near term. As a result of losses, projected cash needs, and current liquidity level, substantial doubt exists about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon successful execution of management’s intended plan over the next twelve months to reduce operating costs and improve the Company’s liquidity, which includes, without limitation: • Reducing operating costs by a reduction in lab and office space through consolidation, and focusing and eliminating certain business activities and services. • Seeking additional capital through the issuance of debt or equity securities, or the sale of assets. While operational improvement efforts and expense control have resulted in margin expansion and stronger financial performance in the nine months ended September 30, 2023, the Company is engaging with stakeholders on a path forward and has formed a special committee of its board of directors focused on improving the Company’s capital position. The Company is exploring a number of options, including, but not limited to, raising capital, asset sales, business and research and development refocusing efforts, capital expenditure and operating expense reductions, and addressing its debt obligations. The condensed consolidated financial statements do not include any adjustments that may result from the outcome of this going concern uncertainty. Since inception, the Company’s operations have been financed primarily by fees collected from its customers, net proceeds from sales of its capital stock as well as borrowing from debt facilities and the issuance of convertible senior notes. The Company will need to raise additional funding to finance operations and service or repay debt obligations, however there is no assurance that it will be successful in obtaining such additional financing. If the Company raises additional capital through debt financing, the Company may be subject to covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, capital expenditures or sale of assets. If the Company raises additional capital through public or private equity offerings, the ownership interest of our existing stockholders would be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the Company’s existing stockholders’ rights. There can be no assurance that additional capital will be available to the Company or, if available, would be available in sufficient amounts or on terms acceptable to us or on a timely basis. If sufficient funds on acceptable terms are not available when needed, the Company could be further required to curtail planned activities to reduce costs, which could include reductions in workforce, elimination of business operations and services, and significant reductions in operating expenses, liquidation of assets or pursuing bankruptcy proceedings. Doing so may potentially have an unfavorable effect on the Company’s ability to execute its business plan and have an adverse effect on the Company’s business, results of operations and future prospects. |
Summary of significant accounti
Summary of significant accounting policies | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Summary of significant accounting policies | 2. Summary of significant accounting policies Principles of consolidation Our unaudited condensed consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base these estimates on current facts, historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those judgments, estimates and assumptions. We evaluate our estimates on an ongoing basis. Prior period reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation. L oss on disposal of property and equipment and impairment charges related to right-of-use assets and the related leasehold improvements are now included in restructuring, impairment and other costs in the condensed consolidated statements of operations. This reclassification had no effect on the previously reported results of operations. Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, restricted cash, marketable securities and accounts receivable. Our cash and cash equivalents are primarily held by financial institutions in the United States. Such deposits often exceed federally insured limits. Cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets are reconciled to the amounts reported in the condensed consolidated statements of cash flows as follows (in thousands): September 30, 2023 September 30, 2022 Cash and cash equivalents $ 158,007 $ 217,029 Restricted cash 10,100 10,027 Total cash, cash equivalents and restricted cash $ 168,107 $ 227,056 Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, operating and finance leases obligations, liabilities associated with business combinations, and convertible senior notes. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to us, the carrying value of our operating and finance leases approximates their fair values. Liabilities associated with business combinations and our 4.50% Series A convertible senior secured notes due 2028 (the “Series A Notes”) and 4.50% Series B convertible senior secured notes due 2028 (the “Series B Notes” and, together with the Series A Notes, the "Senior Secured 2028 Notes") are recorded at their estimated fair value. Fair value option election The fair value option provides an election that allows an entity to irrevocably elect to record certain financial assets and liabilities at fair value on an instrument-by-instrument basis at initial recognition. We have elected to apply the fair value option to the Senior Secured 2028 Notes and stock payable liabilities resulting from business combinations. The Senior Secured 2028 Notes accounted for under the fair value option election pursuant to ASC 825, Financial Instruments, are each a debt host financial instrument containing embedded features that would otherwise be required to be bifurcated from the debt-host and recognized as separate derivative liabilities subject to initial and recurring estimated fair value measurements under ASC 815, Derivatives and Hedging . Notwithstanding, ASC 825 provides for the fair value option election, to the extent not otherwise prohibited by ASC 825, to be afforded to financial instruments. When the fair value option election is applied to financial liabilities, bifurcation of an embedded derivative is not required, and the financial liability is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis as of each reporting period date. The estimated fair value adjustment related to the portion of the change in fair value attributed to a change in the instrument-specific credit risk is recognized as a component of other comprehensive loss, with the remaining amount of the fair value adjustment recognized in other income (expense), net in our condensed consolidated statements of operations. We have elected to present the component related to accrued interest in the change in fair value of the Senior Secured 2028 Notes. In circumstances where an acquisition involves certain indemnification hold-backs that are settled in shares of our common stock, we recognize a stock payable liability based upon the number of shares that are issuable to the sellers and the quoted closing price of our common stock as of the reporting date. The number of shares that will ultimately be issued is subject to adjustment for indemnified claims that existed as of the closing date for each acquisition. We remeasure this liability each reporting period and record changes in the fair value related to stock payable liabilities in other income (expense), net in our condensed consolidated statements of operations. Restructuring, impairment and other costs Restructuring, impairment and other costs are comprised of employee severance and benefits, asset impairments and losses on asset disposals, and other costs. Employee severance and benefit costs are comprised of severance, other termination benefit costs, and stock-based compensation expense for the acceleration of stock awards related to workforce reductions. We recognize costs and liabilities associated with exit and disposal activities in accordance with ASC 420, Exit and Disposal Cost Obligations, and other costs and liabilities associated with nonretirement postemployment benefits in accordance with ASC 712, Nonretirement Postemployment Benefits . Liabilities are based on the estimate of fair value in the period the liabilities are incurred, with subsequent changes to the liability recognized as adjustments in the period of change. We recognize asset impairments and losses on disposals of long-lived assets in accordance with ASC 360, Impairment or Disposal of Long-Lived Assets . Restructuring, impairment and other costs are recognized as an operating expense within the condensed consolidated statements of operations and related liabilities are recorded within accrued liabilities in the condensed consolidated balance sheets. Recent accounting pronouncements We evaluate all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the "FASB") for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on our condensed consolidated financial statements. Recently adopted accounting pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations ("Topic 805"): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments of this ASU require entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers . The Company adopted the amendments in this update on January 1, 2023 with no impact to our condensed consolidated financial statements at the date of adoption. The amendments will be applied prospectively to any future business combinations. |
Revenue, accounts receivable an
Revenue, accounts receivable and deferred revenue | 9 Months Ended |
Sep. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue, accounts receivable and deferred revenue | 3. Revenue, accounts receivable and deferred revenue Test revenue is generated from sales of diagnostic tests and precision oncology products to two groups of customers: patients, consideration for which may be paid directly by the patients or the patients' insurance carriers, and institutions (e.g., hospitals, clinics, medical centers and biopharmaceutical partners). Amounts billed and collected, and the timing of collections, vary based on the type of customer and the corresponding payer, including the patients' insurance carriers that are paying on behalf of the customer. Data and service revenue consists principally of revenue recognized for the performance of activities outlined in biopharmaceutical development contracts and other collaboration and genome network agreements. The following tables present disaggregated revenue by customer and product offering by category (in thousands): Patient Institution Three Months Ended September 30, 2023 Insurance Direct Product: Oncology $ 52,903 $ 1,680 $ 7,162 $ 61,745 Women's health 22,177 3,082 1,597 26,856 Rare diseases 15,534 2,386 5,381 23,301 Data/services — — 9,339 9,339 Total revenue $ 90,614 $ 7,148 $ 23,479 $ 121,241 Patient Institution Three Months Ended September 30, 2022 Insurance Direct Product: Oncology $ 53,104 $ 2,205 $ 23,862 $ 79,171 Women's health 18,887 3,977 1,775 24,639 Rare diseases 8,493 2,577 6,085 17,155 Data/services — — 12,571 12,571 Total revenue $ 80,484 $ 8,759 $ 44,293 $ 133,536 Patient Institution Nine Months Ended September 30, 2023 Insurance Direct Product: Oncology $ 155,663 $ 5,233 $ 20,957 $ 181,853 Women's health 63,921 9,998 4,395 78,314 Rare diseases 40,880 7,337 17,173 65,390 Data/services — — 33,572 33,572 Total revenue $ 260,464 $ 22,568 $ 76,097 $ 359,129 Patient Institution Nine Months Ended September 30, 2022 Insurance Direct Product: Oncology $ 155,298 $ 8,499 $ 68,753 $ 232,550 Women's health 54,963 15,031 6,061 76,055 Rare diseases 23,093 7,806 18,990 49,889 Data/services — — 35,355 35,355 Total revenue $ 233,354 $ 31,336 $ 129,159 $ 393,849 We recognize revenue related to billings based on estimates of the amount that will ultimately be realized. Cash collections for certain tests delivered may differ from rates originally estimated. In subsequent periods, we update our estimate of the amounts recognized for previously delivered tests resulting in the following (decrease) increase to revenue and (decrease) increase to our net (loss) income from operations and basic and diluted net (loss) income per share (in millions, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenue $ (0.3) $ 1.1 $ (4.5) $ 3.5 (Loss) income from operations $ (0.3) $ 1.1 $ (4.5) $ 3.5 Net (loss) income per share, basic and diluted $ — $ — $ (0.02) $ 0.02 Accounts receivable The majority of our accounts receivable represents amounts billed to customers for test, data and service activities, and estimated amounts to be collected from patients' insurance carriers for test services. We record a contract asset for services delivered under certain biopharmaceutical contracts, which are unbilled as of the end of the period. The contract receivable was $1.8 million and $1.3 million as of September 30, 2023 and December 31, 2022, respectively, and was included in prepaid expenses and other current assets in the condensed consolidated balance sheets. Deferred revenue We record a contract liability when cash payments are received or due in advance of our performance related to one or more performance obligations. The deferred revenue balance primarily consists of advanced billings for biopharmaceutical development services, including billings at the initiation of performance-based milestones, and recognized as revenue in the applicable future period when the revenue is earned. Also included are prepayments related to our consumer direct channel. We recognized revenue of $1.9 million and $2.3 million from deferred revenue during the three and nine months ended September 30, 2023, respectively. The current contract liability was $4.8 million as of each of September 30, 2023 and December 31, 2022, which was included in accrued liabilities in the condensed consolidated balance sheets. The long-term contract liability was zero and $0.1 million as of September 30, 2023 and December 31, 2022, respectively, which was included in other long-term liabilities in the condensed consolidated balance sheets. Refund liability As part of our strategic realignment, we terminated early or changed the scope of several companion diagnostic development contracts with milestones in progress. Upon termination, we recorded a refund liability related to the remaining outstanding performance-based milestones. During the three months ended March 31, 2023, we recorded settlement activity associated with the early termination of a companion diagnostic contract. The refund liability was $1.6 million and $4.7 million as of September 30, 2023 and December 31, 2022, respectively, which was included in accrued liabilities in the condensed consolidated balance sheets. Performance obligations |
Intangible Assets, Net
Intangible Assets, Net | 9 Months Ended |
Sep. 30, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible assets, net | 4. Intangible assets, net The following table presents details of our acquired intangible assets as of September 30, 2023 (in thousands): September 30, 2023 Cost Accumulated Asset Disposals/Impairments Net Weighted-Average Customer relationships $ 40,928 $ (20,838) $ (20,090) $ — 10.8 Developed technology 1,138,702 (243,969) (894,733) — 11.1 Trade name 21,072 (5,268) (15,804) — — $ 1,200,702 $ (270,075) $ (930,627) $ — 11.1 The following table presents details of our acquired intangible assets as of December 31, 2022 (in thousands): December 31, 2022 Cost Accumulated Asset Disposals/Impairments Net Weighted-Average Customer relationships $ 41,515 $ (17,675) $ (359) $ 23,481 10.8 Developed technology 1,174,506 (183,133) (19,426) 971,947 10.8 Non-compete agreement 286 (286) — — — Trade name 21,085 (3,964) — 17,121 12.0 Patent assets and licenses 495 (156) (339) — — Right to develop new technology 19,359 (2,474) (16,885) — — $ 1,257,246 $ (207,688) $ (37,009) $ 1,012,549 10.8 Acquisition-related intangibles included in the above tables were generally definite-lived and were carried at cost less accumulated amortization. Customer relationships were being amortized on an accelerated basis in proportion to estimated cash flows. All other definite-lived acquisition-related intangibles were being amortized on a straight-line basis over their estimated lives, which approximated the pattern in which the economic benefits of the intangible assets were expected to be realized. Amortization expense was $25.6 million and $29.6 million for the three months ended September 30, 2023 and 2022, respectively, and $81.9 million and $79.8 million for the nine months ended September 30, 2023 and 2022, respectively. Amortization expense is recorded in cost of revenue, research and development, and selling and marketing expenses in our condensed consolidated statements of operations. Impairment assessment Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events or changes in circumstances indicate that these assets may be impaired. We evaluate the fair value of long-lived assets, which include property and equipment, right-of-use assets and definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. In testing for goodwill impairment, we have the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If we elect to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, we perform a quantitative goodwill impairment test to compare to the fair value of our reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit’s fair value, we will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit’s fair value. During the three months ended June 30, 2022, as a result of the significant, sustained decline in our stock price and related market capitalization and lower than expected financial performance, we performed an impairment assessment of goodwill, IPR&D intangible assets, and long-lived assets, including definite-lived intangibles. Based on this analysis, we recognized a non-cash, pre-tax goodwill impairment charge of $2.3 billion during the three months ended June 30, 2022, which was included in goodwill and IPR&D impairment expense in the condensed consolidated statements of operations. The goodwill was fully impaired as of June 30, 2022. We also identified indicators of impairment related to the IPR&D intangible asset initially recognized as part of the acquisition of Singular Bio, Inc. ("Singular Bio") that it was more likely than not that the asset is impaired. We recognized a non-cash, pre-tax impairment charge of $30.0 million during the three months ended June 30, 2022 related to the IPR&D intangible asset. The impairment charges are recorded in goodwill and IPR&D impairment expense in the condensed consolidated statements of operations. The indefinite-lived intangible asset was fully impaired as of June 30, 2022. Additionally, we recognized a loss on disposal of property and equipment of $4.8 million during the three months ended June 30, 2022 related to specific equipment that is no longer being utilized on this project and has no alternative future use. The loss on disposal is recorded in restructuring, impairment and other costs in the condensed consolidated statements of operations for the nine months ended September 30, 2022. In March 2023, we decided to cease the use of acquired technology focused on informing clinical decisions as management continued our portfolio optimization. During the three months ended March 31, 2023, we wrote-off the remaining carrying value of the related developed technology intangible asset of $2.1 million and recognized $1.0 million for related contractual obligations, which are included in restructuring, impairment and other costs in the condensed consolidated statements of operations for the nine months ended September 30, 2023. See Note 10, "Restructuring, impairment and other costs" for additional information. In June 2023, we decided to cease the use of acquired technology focused on pharmacogenetic testing as management continued our portfolio optimization. During the three months ended June 30, 2023, we wrote-off the remaining carrying value of the related developed technology intangible asset of $5.5 million, which is included in restructuring, impairment and other costs in the condensed consolidated statements of operations for the nine months ended September 30, 2023. See Note 10, "Restructuring, impairment and other costs" for additional information. During the three months ended June 30, 2023, while exploring strategic alternatives in relation to the use of our acquired technology for our patient data platform to help patients collect, organize, store and share their medical records digitally, the developed technology was tested for recoverability. Based on the results of our testing, we wrote-off the remaining carrying value of the related developed technology intangible asset of $74.8 million, which is included in restructuring, impairment and other costs in the condensed consolidated statements of operations for the nine months ended September 30, 2023. In September 2023, we decided to cease the use of acquired technology focused on additional pharmacogenetic testing and cancer risk stratification, along with an acquired tradename. During the three months ended September 30, 2023, we wrote-off the remaining carrying value of the related developed technology and tradename intangible assets of $43.7 million and $15.8 million, respectively, which are included in restructuring, impairment and other costs in the condensed consolidated statements of operations. See Note 10, "Restructuring, impairment and other costs" for additional information. The Company evaluates the carrying value of long-lived assets, which include definite-lived intangible assets, property and equipment, net and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset or asset group may not be fully recoverable. If the sum of the expected future cash flows, on an undiscounted basis, is less than the carrying amount of the asset group, an impairment loss equal to the excess of the carrying amount over the fair value of the individual asset within the asset group is recognized. During the three months ended September 30, 2023, as a result of difficult debt markets to obtain additional financing and the substantial doubt about the Company’s ability to continue as a going concern an impairment assessment of long-lived assets was performed. A recoverability test was performed for the long-lived assets, including definite-lived intangibles, using the undiscounted cash flows approach, which included unobservable inputs including management's forecasts of projected revenue associated with future cash flows, and residual value. The cash flow estimates reflected the Company’s assumptions about its use of the long-lived assets and eventual disposition of the asset group. The Company determined that our long-lived assets held and used, including intangible assets that are subject to amortization, did not have identifiable cash flows that are largely independent of the cash flows of other assets and liabilities and of other asset groups. Therefore, the Company evaluated its long-lived assets for impairment on an entity-wide level. The Company concluded that the carrying value of the entity-wide asset group was not recoverable as it exceeded the future net undiscounted cash flows that are expected to be generated from the use and/or eventual disposition of the asset group. To measure, allocate and recognize the impairment loss, the Company, with the assistance of a third-party valuation specialist, determined the fair value of the asset group using the discounted cash flow method using the income approach. To determine the fair value of the individual assets within the asset group, the Company utilized the discounted cash flow method of the income approach for its intangible assets, the replacement cost less depreciation approach for property and equipment and the income approach for the right-of-use assets. Based on the analysis, the Company recognized non-cash impairment charges of $788.7 million on its definite-lived intangible assets during the three and nine months ended September 30, 2023, which is included in restructuring, impairment and other costs in the condensed consolidated statements of operations. See Note 10, "Restructuring, impairment and other costs" for additional information. The fair value assessments represent Level 3 non-recurring fair value measurements. The fair value of the assets involves unobservable inputs including, but not limited to, management’s forecasts of projected revenue associated with future cash flows and risk-adjusted discount rates. |
Balance sheet components
Balance sheet components | 9 Months Ended |
Sep. 30, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Balance sheet components | 5. Balance sheet components Inventory Inventory consisted of the following (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 21,368 $ 29,992 Work in progress 259 382 Finished goods — 12 Total inventory $ 21,627 $ 30,386 During the second quarter of 2023, management decided to exit certain product offerings. During the three months ended June 30, 2023, we wrote-off the remaining inventory related to these product offerings of $0.7 million, which is included in cost of revenue in the condensed consolidated statements of operations for the nine months ended September 30, 2023. Property and equipment, net Property and equipment consisted of the following (in thousands): September 30, 2023 December 31, 2022 Leasehold improvements $ 56,392 $ 73,095 Laboratory equipment 50,465 67,261 Computer equipment 11,147 13,511 Furniture and fixtures 996 1,427 Construction-in-progress 7,621 21,006 Other 8,110 2,996 Total property and equipment, gross 134,731 179,296 Accumulated depreciation (69,285) (70,573) Total property and equipment, net $ 65,446 $ 108,723 Depreciation expense was $5.2 million and $9.7 million for the three months ended September 30, 2023 and 2022, respectively, and $15.6 million and $21.1 million for the nine months ended September 30, 2023 and 2022, respectively. During the first quarter of 2023, we decided to exit certain leased premises and we recognized a loss on disposal of property and equipment, net of $8.5 million during the three months ended March 31, 2023 for related lab equipment and leasehold improvements, which was included in restructuring, impairment and other costs in our condensed consolidated statements of operations. See Note 4, "Intangible assets, net" for additional information on impairment assessment. During the third quarter of 2023, we decided to exit certain leased premises and we recognized a loss on disposal of property and equipment, net of $21.6 million for the related leasehold improvements, construction-in-process, and computer equipment, which was included in restructuring, impairment and other costs in our condensed consolidated statements of operations. See Note 4, "Intangible assets, net for additional information on impairment assessment. See Note 7, "Commitments and contingencies" and Note 10, "Restructuring, impairment and other costs" for additional information including further discussion related to right-of-use asset impairments. Accrued liabilities Accrued liabilities consisted of the following (in thousands): September 30, 2023 December 31, 2022 Accrued compensation and related expenses $ 39,345 $ 25,315 Accrued litigation expense 20,761 905 Accrued expenses 14,349 23,628 Deferred revenue 4,788 4,814 Other accrued liabilities 3,265 4,568 Accrued royalties 2,176 3,177 Accrued interest 45 6,646 Compensation and other liabilities associated with business combinations — 5,335 Total accrued liabilities $ 84,729 $ 74,388 |
Fair value measurements
Fair value measurements | 9 Months Ended |
Sep. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair value measurements | 6. Fair value measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is summarized as follows: Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable. Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables set forth the fair value of our financial instruments that were measured at fair value on a recurring basis (in thousands): September 30, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Level 1 Level 2 Level 3 Financial assets: Money market funds $ 163,424 $ — $ — $ 163,424 $ 163,424 $ — $ — U.S. Treasury notes 18,848 — (1) 18,847 18,847 — — U.S. government agency securities 77,707 19 (7) 77,719 — 77,719 — Total financial assets $ 259,979 $ 19 $ (8) $ 259,990 $ 182,271 $ 77,719 $ — Financial liabilities: Convertible senior secured notes $ 196,244 $ — $ — $ 196,244 Contingent consideration 25 — — 25 Total financial liabilities $ 196,269 $ — $ — $ 196,269 September 30, 2023 Reported as: Cash equivalents $ 153,324 Restricted cash 10,100 Marketable securities 96,566 Total cash equivalents, restricted cash, and marketable securities $ 259,990 Convertible senior secured notes $ 196,244 Other long-term liabilities 25 Total liabilities $ 196,269 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Level 1 Level 2 Level 3 Financial assets: Money market funds $ 158,931 $ — $ — $ 158,931 $ 158,931 $ — $ — U.S. Treasury notes 193,685 1 (123) 193,563 193,563 — — U.S. government agency securities 96,006 55 (13) 96,048 — 96,048 — Total financial assets $ 448,622 $ 56 $ (136) $ 448,542 $ 352,494 $ 96,048 $ — Financial liabilities: Stock payable liability $ 744 $ — $ — $ 744 Contingent consideration 25 — — 25 Total financial liabilities $ 769 $ — $ — $ 769 December 31, 2022 Reported as: Cash equivalents $ 148,901 Restricted cash 10,030 Marketable securities 289,611 Total cash equivalents, restricted cash, and marketable securities $ 448,542 Other long-term liabilities $ 769 There were no transfers between Level 1, Level 2 and Level 3 during the periods presented. Our debt securities of U.S. government agencies are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third-party data providers, including but not limited to benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data. At September 30, 2023, the remaining contractual maturities of available-for-sale securities ranged from one The total fair value of investments with unrealized losses at September 30, 2023 was $36.1 million. None of the available-for-sale securities held as of September 30, 2023 have been in an unrealized loss position for more than one year. The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of September 30, 2023, because the change in market value of those securities has resulted from fluctuations in market interest rates since the time of purchase, rather than a deterioration of the credit worthiness of the issuers. For marketable securities in an unrealized loss position, we assess our intent to sell, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. We intend to hold our marketable securities to maturity and it is unlikely that they would be sold before their cost bases are recovered. The cost of securities sold is based on the specific identification method. The following tables include a rollforward of the stock payable liability, contingent consideration, and Senior Secured 2028 Notes classified within Level 3 of the fair value hierarchy (in thousands): Three Months Ended September 30, 2023 Stock Payable Liability Contingent Consideration Convertible Senior Secured Notes Fair value at June 30, 2023 $ 251 $ 25 $ 249,571 Issuance of convertible senior secured notes at fair value — — 100 Changes in fair value (70) — (33,463) Changes in fair value related to instrument-specific credit risk — — (16,529) Settlements (181) — — Cash payments for interest — — (3,435) Fair value at September 30, 2023 $ — $ 25 $ 196,244 Nine Months Ended September 30, 2023 Stock Payable Liability Contingent Consideration Convertible Senior Secured Notes Fair value at December 31, 2022 $ 744 $ 25 $ — Issuance of convertible senior secured notes at fair value — — 301,171 Changes in fair value (337) — (72,386) Changes in fair value related to instrument-specific credit risk — — (25,366) Settlements (407) — — Cash payments for interest — — (7,175) Fair value at September 30, 2023 $ — $ 25 $ 196,244 Three Months Ended Stock Payable Liability Contingent Consideration Fair value at June 30, 2022 $ 2,782 $ 25 Change in fair value 527 — Settlements (2,324) — Fair value at September 30, 2022 $ 985 $ 25 Nine Months Ended Stock Payable Liability Contingent Consideration Fair value at December 31, 2021 $ 20,925 $ 1,875 Change in fair value (15,666) (1,850) Settlements (4,274) — Fair value at September 30, 2022 $ 985 $ 25 Stock payable liabilities relate to certain indemnification hold-backs resulting from business combinations that are settled in shares of our common stock. We elected to account for these liabilities using the fair value option due to the inherent nature of the liabilities and the changes in value of the underlying shares that will ultimately be issued to settle the liabilities. The estimated fair value of these liabilities is classified as Level 3 and determined based upon the number of shares that are issuable to the sellers and the quoted closing price of our common stock as of the reporting date. The number of shares that will ultimately be issued is subject to adjustment for indemnified claims that existed as of the closing date for each acquisition. Changes in the number of shares issued and share price can significantly affect the estimated fair value of the liabilities. The change in fair value related to stock payable liabilities was income of $0.1 million and $0.5 million during the three months ended September 30, 2023 and 2022, respectively, and income of $0.4 million and $15.7 million for the nine months ended September 30, 2023 and 2022, respectively, which was recorded in change in fair value of acquisition-related liabilities in the condensed consolidated statements of operations. Contingent consideration relates to the obligation we may be required to pay in the form of additional shares of our common stock resulting from the acquisition of Genelex in April 2020. The amount of the contingent obligation is dependent upon the achievement of a certain product milestone, at which time we would issue shares of our common stock with a value equal to a portion of the gross revenues actually received by us for a pharmacogenetic product reimbursed through certain payers during an earn-out period of up to four years. The estimated fair value of the contingent consideration is based upon significant inputs not observable in the market and, therefore, represents a Level 3 measurement. The material factors that may impact the fair value of the contingent consideration, and therefore, this liability, are the probabilities and timing of achieving the related milestone, the estimated revenues achieved for a pharmacogenetic product and the discount rate used to estimate the fair value. Significant changes in any of the probabilities of success would result in a significant change in the estimated fair value of the liability. The change in fair value related to contingent consideration recorded to general and administrative expense was zero during both the three months ended September 30, 2023 and 2022, respectively, and zero and a gain of $1.8 million during the nine months ended September 30, 2023 and 2022, respectively. In March 2023, the Company issued Series A Notes in an aggregate principal amount of $275.3 million, and Series B Notes in an aggregate principal amount of $30.0 million. In August 2023, the Company issued additional Series A Notes in an aggregate principal amount of $0.1 million. The Company elected the fair value option to account for the Senior Secured 2028 Notes. We utilize the binomial lattice model, specifically a lattice model to estimate the fair value of the Senior Secured 2028 Notes at issuance and subsequent reporting dates. The estimated fair value of the Senior Secured 2028 Notes is determined using Level 3 inputs and assumptions unobservable in the market. This model incorporates the terms and conditions of the Senior Secured 2028 Notes and assumptions related to stock price, expected stock price volatility, risk-free interest rate, market credit spread, and cost of debt. The stock price is based on the publicly traded price of our common stock as of the measurement date. We estimate the volatility of our stock price based on the historical and implied volatilities of our publicly traded common stock. The risk-free interest rate is based on interpolated U.S. Treasury rates, commensurate with a similar term to the Senior Secured 2028 Notes. The most significant assumptions in the binomial lattice model impacting the fair value of the Senior Secured 2028 Notes are (i) the estimated stock price, (ii) the estimated cost of debt, and (iii) the volatility of our common stock. Significant changes in any of these inputs may result in a significant change in the fair value of the Senior Secured 2028 Notes. Under the fair value election as prescribed by ASC 825, we record changes in fair value, inclusive of related accrued interest, through the condensed consolidated statements of operations as a fair value adjustment of the convertible senior secured debt each reporting period, with the portion of the change that results from a change in the instrument-specific credit risk recorded separately in other comprehensive loss, if applicable. The portion of total changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the risk-free interest rate, credit spread, and cost of debt assumptions. The initial carrying amount of the Senior Secured 2028 Notes, measured at the estimated fair value on the date of issuance, was $301.1 million. As of September 30, 2023, the estimated fair value was $196.2 million. During the three and nine months ended September 30, 2023, the corresponding change in fair value of the Senior Secured 2028 Notes was a gain of $33.5 million and $72.4 million, respectively, which is included in other income (expense), net in the condensed consolidated statements of operations. The change in fair value related to instrument-specific credit risk was $16.5 million and $25.4 million during the three and nine months ended September 30, 2023, respectively, which is included in the condensed consolidated statements of comprehensive loss. See Note 7, "Commitments and contingencies" under the heading "Convertible senior notes—Convertible senior secured notes due 2028" for a description of the Senior Secured 2028 Notes. Significant inputs into the binomial lattice model as of September 30, 2023 and March 7, 2023 were as follows: September 30, 2023 March 7, 2023 Stock price $0.61 $1.65 Conversion price $2.58 $2.58 Volatility 110.0 % 107.5 % Risk-free interest rate 4.71 % 4.35 % Credit spread 17.92 % 13.76 % Cost of debt 22.6 % 18.1 % Term (years) 4.46 5.02 |
Commitments and contingencies
Commitments and contingencies | 9 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and contingencies | 7. Commitments and contingencies Leases The Company has entered into various non-cancellable operating lease agreements for office and laboratory space domestically and internationally. The Company's current leases have remaining terms ranging from approximately 1 to 12 years, some of which include options to extend the leases. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as they are not reasonably certain of being exercised. The security deposits for our operating leases are included in restricted cash in our condensed consolidated balance sheets. In 2015, we entered into a non-cancelable operating lease agreement for our headquarters and main production facility in San Francisco, California, which commenced in 2016 with an initial lease term extending through 2026. In 2020, we entered into a non-cancelable operating lease agreement for additional office and laboratory space in San Francisco, California, which commenced in 2021 and has an initial lease term extending through 2031. In 2021, we entered into a non-cancelable operating lease agreement for a new laboratory and production facilities in Morrisville, North Carolina, which commenced in the same year with an initial lease term extending through 2035. See the discussion below regarding management's decision to exit the operating leases for additional office and laboratory space in San Francisco, California and the new laboratory and production facilities in Morrisville, North Carolina and the related impairments in 2023. We have entered into various finance lease agreements to obtain laboratory equipment. The terms of our finance leases are generally three years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayment and related interest was classified as a finance lease obligation in our condensed consolidated balance sheets. Finance lease assets are recorded within other assets in our condensed consolidated balance sheets. During the first quarter of 2023, we decided to exit certain leased premises and actively began looking to sublease certain facilities, including the related leasehold improvements. We determined that the changes in the intended use of these locations represented an indicator of impairment and performed a test of recoverability as of March 31, 2023. For operating leases where the carrying values of the asset group were higher than the undiscounted cash flows expected through sublease, we impaired the asset group to their fair value. The fair value was determined by utilizing the discounted cash flow method under the income approach. The key inputs to this valuation were expected sublease rental income ranging from $7.6 million to $35.7 million and a discount rate ranging from 7.0% to 8.0%. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement. During the three months ended March 31, 2023, we recognized an impairment charge of $37.8 million related to the right-of-use assets and $2.0 million for the related leasehold improvements, which was included in restructuring, impairment and other costs in our condensed consolidated statements of operations. During the first quarter of 2023, we reassessed certain leases previously impaired as part of the strategic realignment for additional impairment due to the continued decline in market conditions and changes in the ability to sublease the properties. We determined that the changes in market conditions represented an indicator of impairment and performed a test of recoverability as of March 31, 2023. For operating leases where the carrying values of the asset group were higher than the undiscounted cash flows expected through sublease, we further impaired the asset group to their fair value. The fair value was determined by utilizing the discounted cash flow method under the income approach. The key inputs to this valuation were expected sublease rental income ranging from $0.3 million to $1.9 million and discount rates ranging from 7.50% to 7.75%. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement. During the three months ended March 31, 2023, we recognized an impairment charge of $2.3 million related to the right-of-use assets, which was included in restructuring, impairment and other costs in our consolidated statements of operations. During the second quarter of 2023, we reassessed certain leases previously impaired as part of the strategic realignment for additional impairment due to the continued decline in market conditions and changes in the ability to sublease the properties. We determined that the changes in market conditions represented an indicator of impairment and performed a test of recoverability as of June 30, 2023. For operating leases where the carrying values of the asset group were higher than the undiscounted cash flows expected through sublease, we further impaired the asset group to their fair value. The fair value was determined by utilizing the discounted cash flow method under the income approach. The key inputs to this valuation were expected sublease rental income ranging from $0.1 million to $0.4 million and a discount rate of 7.75%. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement. During the three months ended June 30, 2023, we recognized an impairment charge of $0.6 million related to the right-of-use assets, which was included in restructuring, impairment and other costs in our consolidated statements of operations. During the third quarter of 2023, we decided to exit certain leased premises and actively began looking to sublease certain facilities, including the related leasehold improvements. We determined that the changes in the intended use of these locations represented an indicator of impairment and performed a test of recoverability as of September 30, 2023. For operating leases where the carrying values of the asset group were higher than the undiscounted cash flows expected through sublease, we impaired the asset group to their fair value. The fair value was determined by utilizing the discounted cash flow method under the income approach. The key inputs to this valuation were expected sublease rental income of $50.9 million and a discount rate of 7.5%. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement. During the three months ended September 30, 2023, we recognized an impairment charge of $9.9 million related to the right-of-use assets and $17.1 million for the related leasehold improvements, which was included in restructuring, impairment and other costs in our condensed consolidated statements of operations. During the third quarter of 2023, we reassessed certain leases previously impaired as part of the strategic realignment for additional impairment due to the continued decline in market conditions and changes in the ability to sublease the properties. We determined that the changes in market conditions represented an indicator of impairment and performed a test of recoverability as of September 30, 2023. For operating leases where the carrying values of the asset group were higher than the undiscounted cash flows expected through sublease, we impaired the asset group to their fair value. The fair value was determined by utilizing the discounted cash flow method under the income approach. The key inputs to this valuation were expected sublease rental income ranging from less than $0.1 million to $33.6 million and a discount rate range of 7.50% to 7.75%. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement. During the three months ended September 30, 2023, we recognized an impairment charge of $0.6 million related to the right-of-use assets which was included in restructuring, impairment and other costs in our condensed consolidated statements of operations. During the three months ended September 30, 2023, as a result of the exit of the leased space described above, the Company also recognized an impairment charge of $0.8 million related to a finance lease which was included in restructuring, impairment and other costs in our condensed consolidated statements of operations. Sublease income was $0.4 million and $1.1 million during the three and nine months ended September 30, 2023, respectively, which is included in other income (expense), net in the condensed consolidated statements of operations. There was no sublease income for the three and nine months ended September 30, 2022, respectively. Debt financing In October 2020, we entered into a credit agreement with a financial institution under which we borrowed $135.0 million (the "2020 Term Loan") concurrent with the closing of the ArcherDX, Inc. ("ArcherDX") acquisition. The 2020 Term Loan bore interest at an annual rate equal to three-month LIBOR, subject to a 2.00% LIBOR floor, plus a margin of 8.75%. If the 2020 Term Loan is prepaid (whether such prepayment is optional or mandatory), we were required to pay a prepayment fee of 6% if the prepayment occurs prior to the third anniversary of the closing date or 4% if the prepayment occurs after the third anniversary of the closing date and we were also required to pay a make-whole fee if the prepayment occurs prior to the second anniversary of the closing date. Debt discounts, including debt issuance costs, related to the 2020 Term Loan of $32.8 million were recorded as a direct deduction from the debt liability and are being amortized to interest expense over the term of the 2020 Term Loan. Interest expense related to our debt financings, excluding the impact of our convertible senior notes (defined below), was zero and $6.0 million for the three months ended September 30, 2023 and 2022, respectively, and $4.1 million and $17.8 million for the nine months ended September 30, 2023 and 2022, respectively. In February 2023, we repaid, prior to the maturity date, the principal balance outstanding of $135.0 million plus accrued interest of $2.6 million. During the three months ended March 31, 2023, we incurred debt extinguishment costs of $19.3 million related to the prepayment, which included the write-off of unamortized debt issuance costs of $11.2 million and prepayment fees of $8.1 million, which was included in loss on extinguishment of debt, net in the condensed consolidated statements of operations. Convertible senior notes Convertible senior notes due 2024 In September 2019, we issued, at par value, $350.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 (the "2024 Notes") in a private offering. The 2024 Notes are our senior unsecured obligations and will mature on September 1, 2024, unless earlier converted, redeemed or repurchased. The 2024 Notes bear cash interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2020. Upon conversion, the 2024 Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. The initial conversion rate for the 2024 Notes is 33.6293 shares of our common stock per $1,000 principal amount of the 2024 Notes (equivalent to an initial conversion price of approximately $29.74 per share of common stock). If we undergo a fundamental change (as defined in the indenture governing the 2024 Notes), the holders of the 2024 Notes may require us to repurchase all or any portion of their 2024 Notes for cash at a repurchase price equal to 100% of the principal amount of the 2024 Notes to be repurchased plus accrued and unpaid interest to, but excluding, the redemption date. The 2024 Notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding March 1, 2024, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2019 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2024 Notes on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of 2024 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the 2024 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after March 1, 2024 until the close of business on the business day immediately preceding the maturity date, holders may convert their 2024 Notes at any time, regardless of the foregoing circumstances. Since issuance, these notes were convertible at the option of the holders during the quarters beginning on January 1, 2021 and April 1, 2021 due to the sale price of our common stock during the quarters ended December 31, 2020 and March 31, 2021, respectively. The notes were not convertible during the nine months ended September 30, 2023 and there have been no significant conversions in the periods in which they were convertible. We may redeem for cash all or any portion of the 2024 Notes, at our option, on or after September 6, 2022 and on or before the 30th scheduled trading day immediately before the maturity date if the last reported sale price of the common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. See the discussion below regarding the purchase and exchange agreements with certain holders of the outstanding 2024 Notes. As of September 30, 2023, the outstanding principal balance of the 2024 Notes was $27.1 million. Convertible senior notes due 2028 In April 2021, we issued, at 99% of par value, $1,150.0 million aggregate principal amount of 1.5% convertible senior notes due 2028 (the "2028 Notes") in a private offering. The 2028 Notes are our senior unsecured obligations and will mature on April 1, 2028, unless earlier converted, redeemed or repurchased. The 2028 Notes bear cash interest at a rate of 1.5% per year, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021. Upon conversion, the 2028 Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. The 2028 Notes will be convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by us. The 2028 Notes will be convertible into shares of our common stock based on an initial conversion rate of 23.1589 shares of common stock per $1,000 principal amount of the 2028 Notes (which is equal to an initial conversion price of $43.18 per share), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. None of the 2028 Notes have been converted to date. We may not redeem the 2028 Notes prior to April 6, 2025. On or after April 6, 2025, the 2028 Notes will be redeemable by us in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2028 Notes, plus accrued and unpaid interest to, but excluding, the redemption date. With certain exceptions, upon a change of control of the Company or the failure of our common stock to be listed on certain stock exchanges, the holders of the 2028 Notes may require that we repurchase all or part of the principal amount of the Notes at a repurchase price of 100% of the principal amount of the 2028 Notes to be repurchased, plus unpaid interest to, but excluding, the maturity date. Summary of convertible senior notes Our 2024 Notes and 2028 Notes (collectively, our "Convertible Senior Notes") consisted of the following (in thousands): September 30, 2023 December 31, 2022 Outstanding principal $ 1,177,058 $ 1,499,996 Unamortized debt discount and issuance costs (22,321) (29,213) Net carrying amount $ 1,154,737 $ 1,470,783 As of September 30, 2023, the estimated fair value of the 2024 Notes and 2028 Notes w as $24.5 million and $445.7 million, respectively. The estimated fair value of the 2024 Notes and 2028 Notes, which use Level 2 fair value inputs, was determined based on yields on debt of companies with similar credit risk, debt maturity and market conditions including the price and volatility of our common stock and comparable company information. The effective interest rates were 2.54% and 1.95% for the 2024 Notes and 2028 Notes, respectively. We recognized $5.7 million and $7.7 million of interest expense related to our Convertible Senior Notes during the three months ended September 30, 2023 and 2022, respectively, and $18.7 million and $23.1 million during the nine months ended September 30, 2023 and 2022, respectively. Of the interest expense recognized, $1.3 million and $1.7 million during the three months ended September 30, 2023 and 2022, respectively, and $4.0 million and $5.0 million during the nine months ended September 30, 2023 and 2022, respectively, was related to amortization of issuance costs and the remainder was related to contractual interest incurred. Convertible senior secured notes due 2028 In February 2023, we entered into purchase and exchange agreements with certain holders of the outstanding 2024 Notes. Under the terms of the agreements, we (a) exchanged $305.7 million aggregate principal amount of 2024 Notes for $275.3 million aggregate principal amount of Series A Notes and 14,219,859 shares of the Company’s common stock and (b) issued and sold $30.0 million aggregate principal amount of Series B Notes for cash. In August 2023, we entered into an exchange agreement with a holder of outstanding 2024 Notes. Under the terms of the agreement, we exchanged $17.2 million aggregate principal amount of the 2024 Notes for $0.1 million aggregate principal amount of Series A Notes and 15,819,604 shares of the Company's common stock. The Senior Secured 2028 Notes are our senior secured obligations and will mature on March 15, 2028, unless earlier converted, redeemed or repurchased. The Senior Secured 2028 Notes bear cash interest at a rate of 4.50% per year, payable quarterly in arrears on March 15, June 15, September 15 and December 15 of each year, beginning on June 15, 2023. Based on the initial conversion price of $2.58, the Senior Secured 2028 Notes will be initially convertible into an aggregate of 118,316,667 shares of common stock, and after taking into account the maximum number of additional shares issuable in certain circumstances as described in the indenture, an aggregate of 141,979,975 shares of common stock. At any time prior to the 60th day prior to the maturity date of the Senior Secured 2028 Notes, we have the option to redeem all or any portion of the principal amount of the Senior Secured 2028 Notes for cash equal to the principal amount of the Senior Secured 2028 Notes to be redeemed. Upon redemption of any Senior Secured 2028 Notes, we will (i) issue warrants to purchase shares of common stock, unless the aggregate principal amount of Senior Secured 2028 Notes outstanding represents less than 10% of the aggregate principal amount of Senior Secured 2028 Notes initially issued and certain other conditions are satisfied, and (ii) make a make-whole payment as determined pursuant to the indenture governing the Senior Secured 2028 Notes, together with accrued and unpaid interest through the redemption date. In addition, in certain circumstances, we may be required to issue additional shares of common stock for any Senior Secured 2028 Notes converted in connection with a notice of optional redemption. The indenture governing the Senior Secured 2028 Notes also provides for the issuance of warrants to purchase shares of common stock in connection with the prepayment of the Senior Secured 2028 Notes upon acceleration of the Senior Secured 2028 Notes following the occurrence of an event of default under the indenture as a result of the failure by the Company to settle any conversion. Any warrants issued will cover the same number of shares of the common stock underlying and at an exercise price equal to the conversion price of the redeemed or prepaid Senior Secured 2028 Notes. The number of shares issuable upon conversion or exercise is subject to customary anti-dilution and other adjustments (as defined in the indenture governing the Senior Secured 2028 Notes). The Senior Secured 2028 Notes will be convertible at any time prior to the maturity date at the option of the holders, subject to a beneficial ownership cap. If we undergo a major transaction (as defined in the indenture), holders may require us to repurchase for cash all or part of their Senior Secured 2028 Notes at a purchase price equal to 100% of the principal amount of the Senior Secured 2028 Notes to be repurchased, plus (i) accrued and unpaid interest to, but excluding, the repurchase date and (ii) the make-whole amount as determined pursuant to the indenture governing the Senior Secured 2028 Notes. In addition, at the election of the holders of the Senior Secured 2028 Notes, we may be required to issue additional shares of common stock for any Senior Secured 2028 Notes converted in connection with a major transaction. The Senior Secured 2028 Notes are guaranteed by our material subsidiaries and secured by (i) a security interest in substantially all of the assets of the Company and its domestic material subsidiaries and (ii) a pledge of the equity interests of the Company's direct and indirect subsidiaries, subject to certain customary exceptions. The indenture contains certain specified events of default, the occurrence of which would entitle the holders of the Senior Secured 2028 Notes to demand repayment of all outstanding principal and accrued interest on the Notes, together with a make-whole payment as determined pursuant to the indenture. The indenture also includes specific affirmative and restrictive covenants agreed to by the Company. In addition, the indenture also contains financial covenants that will require us to maintain revenue in the prior four quarters of not less than $250.0 million and, starting with the quarter ending March 31, 2025, a minimum liquidity of at least 15% of the amount of our secured indebtedness then outstanding. As of September 30, 2023, we are in compliance with all restrictive and financial covenants. We elected the fair value option to account for the Senior Secured 2028 Notes, which requires the notes to be accounted for as a single liability initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis as of each reporting date. We have elected not to present the interest expenses separate from the fair value changes of the Senior Secured 2028 Notes. Considering the terms of settlement noted above, we elected the fair value option for the Senior Secured 2028 Notes as we believe it best reflects the underlying economics and also for simplification and cost-benefit considerations of accounting such Senior Secured 2028 Notes at fair value versus bifurcation of the embedded derivatives. The initial carrying amount of the Senior Secured 2028 Notes, measured at the estimated fair value on the date of issuance, was $301.1 million. As of September 30, 2023, the estimated fair value of the Senior Secured 2028 Notes was $196.2 million and was recorded as a long-term liability in the condensed consolidated balance sheets. Classification of the Senior Secured 2028 Notes as a long-term liability represents our intent and ability to settle the obligations by issuing shares. During the three and nine months ended September 30, 2023, the corresponding change in fair value of the Senior Secured 2028 Notes was a gain of $33.5 million and $72.4 million, respectively, which was included in other income (expense), net in the condensed consolidated statements of operations. During the three and nine months ended September 30, 2023, the change in fair value related to instrument-specific credit risk was $16.5 million and $25.4 million, respectively, which was included in the condensed consolidated statements of comprehensive loss. In connection with the issuance of the Senior Secured 2028 Notes, we incurred approximately $19.9 million of debt issuance costs primarily related to legal and consulting fees paid to third parties, which were expensed as incurred during the three months ended March 31, 2023 and included in other income (expense), net in the condensed consolidated statements of operations. The exchange of the 2024 Notes for the Senior Secured 2028 Notes was treated as an extinguishment of debt. During the three months ended March 31, 2023, we recognized a gain on extinguishment of $8.5 million representing the difference between the fair value of the Series A Notes immediately prior to the exchange plus the fair value of common shares issued and the carrying amount of the 2024 Notes, which was included in loss on extinguishment of debt, net in the condensed consolidated statements of operations. During the three months ended September 30, 2023, in connection with the issuance of the additional Series A Notes, we incurred approximately $0.7 million of debt issuance costs primarily related to legal and consulting fees paid to third parties, which were expensed as incurred and were included in other income (expense), net in the condensed consolidated statements of operations. The exchange of the 2024 Notes for the Series A Notes was treated as an extinguishment of debt. During the three months ended September 30, 2023, we recognized a gain on extinguishment of $0.2 million representing the difference between the fair value of the Series A Notes immediately prior to the exchange plus the fair value of common shares issued and the carrying amount of the 2024 Notes, which was included in gain (loss) on extinguishment of debt, net in the condensed consolidated statements of operations. Other commitments In the normal course of business, we enter into various purchase commitments primarily related to service agreements and laboratory supplies. At September 30, 2023, our total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year wer e $16.2 million. As of September 30, 2023, the total remaining commitment due and expected to be fulfilled in 2023 including through the purchase of the sequencing consumables and equipment is $11.6 million. See Note 10, "Restructuring, impairment and other costs" for additional information. Guarantees and indemnification As permitted under Delaware law and in accordance with our bylaws, we indemnify our directors and officers for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of potential future indemnification is unlimited; however, we maintain director and officer liability insurance. This insurance allows the transfer of the risk associated with our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements is minimal. Accordingly, we did not record any liabilities associated with these indemnification agreements at September 30, 2023 or December 31, 2022. Contingencies We are and may from time to time be involved in various legal proceedings and claims arising in the ordinary course of business. Legal proceedings, including litigation, government investigations and enforcement actions could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if we ultimately prevail. If an investigation results in a proceeding against us, an adverse outcome could include us being required to pay treble damages, and incur attorneys’ fees, civil or criminal penalties and other adverse actions that could materially and adversely affect our business, financial condition and results of operations. While we believe any such claims are unsubstantiated, and we believe we are in compliance with applicable laws and regulations applicable to our business, the resolution of any such claims could be material. We were not a party to any material legal proceedings at September 30, 2023, or at the date of this report except for matters listed below. We cannot currently predict the outcome of these actions. Natera, Inc. On January 27, 2020, Natera filed a lawsuit against ArcherDX (a subsidiary of Invitae effective October 2, 2020) in the United States District Court for the District of Delaware, alleging that ArcherDX’s products using Anchored Multiplex PCR ("AMP") chemistry, and the manufacture, use, sale, and offer for sale of such products, infringe U.S. Patent No. 10,538,814. On March 25, 2020, ArcherDX filed an answer denying Natera’s allegations and asserting certain affirmative defenses and counterclaims, including that U.S. Patent No. 10,538,814 is invalid and not infringed. On April 15, 2020, Natera filed an answer denying ArcherDX’s counterclaims and filed an amended complaint alleging that ArcherDX’s products using AMP chemistry, including STRATAFIDE, PCM, LiquidPlex, ArcherMET, FusionPlex, and VariantPlex, and the manufacture, use, sale, and offer for sale of such products, infringe U.S. Patent No. 10,538,814, U.S. Patent No. 10,557,172, U.S. Patent No. 10,590,482, and U.S. Patent No. 10,597,708, each of which is held by Natera. Natera seeks, among other things, damages and other monetary relief, costs and attorneys’ fees, and an order enjoining ArcherDX from further infringement of such patents. On May 13, 2020, ArcherDX filed an answer to Natera’s amended complaint denying Natera’s allegations and asserting certain affirmative defenses and counterclaims, including that the asserted patents are invalid and not infringed. On June 3, 2020, Natera filed an answer denying ArcherDX’s counterclaims. On June 4, 2020, ArcherDX filed a motion seeking dismissal of Natera’s infringement claims against STRATAFIDE, PCM, and ArcherMET, and for a judgment that U.S. Patent No. 10,538,814, U.S. Patent No. 10,557,172, and U.S. Patent No. 10,590,482 are invalid. On August 6, 2020, Natera filed another complaint against ArcherDX in the United States District Court for the District of Delaware alleging that ArcherDX’s products using AMP chemistry, including STRATAFIDE, PCM, LiquidPlex, ArcherMET, and VariantPlex, and the manufacture, use, sale, and offer for sale of such products, infringe U.S. Patent No. 10,731,220. Natera seeks, among other things, damages and other monetary relief, costs and attorneys’ fees, and an order enjoining ArcherDX from further infringement of the patent. On October 13, 2020, the court issued an order denying ArcherDX's motion for dismissal of Natera’s infringement claims against STRATAFIDE, PCM, and ArcherMET, and declined to enter judgment that U.S. Patent No. 10,538,814, U.S. Patent No. 10,557,172, and U.S. Patent No. 10,590,482 are invalid. On January 12, 2021, the court issued an order granting N |
Stockholders' equity
Stockholders' equity | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Stockholders' equity | 8. Stockholders' equity Shares outstanding Shares of common stock were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Common stock: Shares outstanding, beginning of period 266,762 234,767 245,562 228,116 Common stock issued in connection with the convertible senior notes exchange 15,820 — 30,040 — Common stock issued in connection with public offering 50 2,429 50 2,429 Common stock issued on exercise of stock options, net — 17 2 150 Common stock issued pursuant to vesting of RSUs 3,408 4,645 8,374 9,401 Common stock issued pursuant to employee stock purchase plan — — 1,835 1,535 Common stock issued pursuant to acquisitions 453 972 630 1,199 Shares outstanding, end of period 286,493 242,830 286,493 242,830 Common Stock As of September 30, 2023 and December 31 2022, we had 600 million shares of common stock authorized with a par value of $0.0001. Convertible preferred stock In August 2017, in a private placement to certain accredited investors, we issued shares of our Series A convertible preferred stock which are convertible into common stock on a one-for-one basis, subject to adjustment for events such as stock splits, combinations and the like. The Series A convertible preferred stock is a non-voting common stock equivalent with a par value of $0.0001 and has the right to receive dividends first or simultaneously with payment of dividends on common stock. In the event of any liquidation or dissolution of the Company, the Series A preferred stock is entitled to receive $0.001 per share prior to the payment of any amount to any holders of capital stock ranking junior to the Series A preferred stock and thereafter shall participate pari passu with the holders of our common stock (on an as-if-converted-to-common-stock basis). As of September 30, 2023 and December 31, 2022, we had 20 million shares of preferred stock authorized, of which 3,458,823 shares were designated as Series A convertible preferred stock. As of September 30, 2023 and December 31, 2022, there were no shares of preferred stock or Series A convertible preferred stock outstanding. Sales Agreement In May 2021, we entered into a sales agreement (the "2021 Sales Agreement") with Cowen and Company, LLC (“Cowen”) under which we may offer and sell from time to time at our sole discretion shares of our common stock through Cowen as our sales agent, in an aggregate amount not to exceed $400.0 million. Per the terms of the agreement, Cowen will receive a commission of up to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2021 Sales Agreement. During the three and nine months ended September 30, 2023, we sold 50,400 shares of common stock under the 2021 Sales Agreement at a price of $1.10 per share, for gross proceeds of $0.1 million and gross fees of $0.1 million. During the three and nine months ended September 30, 2022, we sold 2.4 million shares of common stock under the 2021 Sales Agreement at a weighted average price of $3.99 per share, for gross proceeds of $10.0 million and net proceeds of $9.7 million. Senior Secured 2028 Notes In connection with the issuance of the Senior Secured 2028 Notes on March 7, 2023, we and Deerfield Partners, L.P. (the "selling stockholder"), also entered into a registration rights agreement ("Registration Rights Agreement"). Pursuant to the Registration Rights Agreement, on March 17, 2023, we filed a registration statement to register 111,627,888 shares of common stock issuable upon conversion of the Series B Notes or exercise of the warrants ("Registrable Securities") issuable in connection with certain prepayments of the Series B Notes or Series A Notes, which registration statement was declared effective on April 21, 2023. The selling stockholder may from time to time offer and sell any or all of such issued shares of common stock. We will not receive any proceeds from the sale of shares of our common stock by the selling stockholder. We will receive the proceeds from any exercise of the warrants on a cash basis. Additionally, under the terms of the purchase and exchange agreements, we exchanged $305.7 million aggregate principal amount of 2024 Notes for $275.3 million aggregate principal amount of Series A Notes and 14,219,859 shares of the Company’s common stock, and we issued and sold $30.0 million aggregate principal amount of Series B Notes for cash. See Note 7, "Commitments and contingencies" under the heading "Convertible senior notes—Convertible senior secured notes due 2028" for additional information. In August 2023, we entered into an exchange agreement with a holder of outstanding 2024 Notes. Under the terms of the agreement, we exchanged $17.2 million aggregate principal amount of the 2024 Notes for $0.1 million aggregate principal amount of Series A Notes and 15,819,604 shares of the Company's common stock. |
Stock incentive plans
Stock incentive plans | 9 Months Ended |
Sep. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Stock incentive plans | 9. Stock incentive plans Stock incentive plans In 2010, we adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors and consultants under terms and provisions established by our board of directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than the fair market value of our common stock. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least 110% of fair market value of our common stock on the grant date, as determined by our board of directors. The terms of options granted under the 2010 Plan may not exceed ten years. In January 2015, we adopted the 2015 Stock Incentive Plan (the “2015 Plan”), which became effective upon the closing of our initial public offering. Shares outstanding under the 2010 Plan were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards. Options granted generally vest over a period of four years. Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the award vests upon the first anniversary of the employee’s date of hire, with the remainder of the award vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the four-year vesting schedule. Upon the acquisition of ArcherDX in October 2020, any option that was outstanding was converted into a fully vested option to purchase a share of our common stock, which resulted in the issuance of options to purchase 3.7 million shares of our common stock. Restricted stock units ("RSUs") generally vest ratably in quarterly installments over a period of two years, with certain awards that include a portion that vests immediately upon grant. The vesting schedule for grants to the executive team and periods prior to 2022 generally vest ratably in annual installments over a period of three years, commencing on the first anniversary of the grant date. We have also granted certain awards in connection with our management incentive plan that vest over a period of two years. Performance-based restricted stock units ("PRSUs") vest upon the achievement of certain performance conditions subject to the employees' continued service relationship with us. In April 2021, we granted RSUs in connection with the acquisition of Genosity Inc. ("Genosity") having a value of up to $5.0 million to certain continuing employees. We recognized stock-based compensation expense of $0.4 million during each of the three months ended September 30, 2023 and 2022, respectively, and $1.2 million and $1.3 million during the nine months ended September 30, 2023 and 2022, respectively, which was primarily included in research and development expense in our condensed consolidated statements of operations. In September 2021, we granted RSUs in connection with the acquisition of the Ciitizen Corporation ("Ciitizen") having a value of up to $246.9 million to certain continuing employees. We recognized stock-based compensation expense of $15.8 million and $22.2 million during the three months ended September 30, 2023 and 2022, respectively, and $46.7 million and $72.2 million during the nine months ended September 30, 2023 and 2022, respectively, which was primarily included in research and development expense in our condensed consolidated statements of operations. Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share data and years): Shares Available For Grant Stock Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balances at December 31, 2022 12,625 2,541 $ 8.49 6.6 $ 16 Additional shares reserved 9,822 — Options granted (325) 325 1.46 Options cancelled 381 (381) 9.25 Options exercised — (2) 0.86 RSUs and PRSUs granted (17,448) — RSUs and PRSUs cancelled 2,835 — Balances at September 30, 2023 7,890 2,483 $ 7.46 6.7 $ — Options exercisable at September 30, 2023 1,498 $ 9.78 5.2 $ — Options vested and expected to vest at September 30, 2023 2,335 $ 7.76 6.5 $ — The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of our common stock for stock options that were in-the-money. The following table summarizes RSU, including PRSU, activity (in thousands, except per share data): Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2022 11,895 $ 11.70 RSUs granted 17,448 $ 1.12 RSUs vested (8,374) $ 13.81 RSUs cancelled (2,835) $ 7.02 Balance at September 30, 2023 18,134 $ 1.28 Stock-based compensation The following table summarizes stock-based compensation expense included in the condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of revenue $ 755 $ 1,203 $ 2,791 $ 5,702 Research and development 19,081 24,301 58,800 94,661 Selling and marketing 1,354 2,625 6,245 10,498 General and administrative 4,755 7,477 17,661 28,646 Restructuring, impairment and other costs 52 24,807 57 24,807 Total stock-based compensation expense $ 25,997 $ 60,413 $ 85,554 $ 164,314 Stock-based compensation expense included in restructuring expense was primarily related to the accelerated vesting of RSUs held by certain employees whose employment was terminated as part of the strategic realignment. Additionally, certain employees were granted retention-related RSUs in August 2022 as part of the strategic realignment, which vest on the first anniversary of the grant date. During the three months ended June 30, 2023, two employees that were granted retention-related RSUs exited the Company, which resulted in the reversal of the related stock-based compensation expense. |
Restructuring, impairment and o
Restructuring, impairment and other costs | 9 Months Ended |
Sep. 30, 2023 | |
Restructuring and Related Activities [Abstract] | |
Restructuring, impairment and other costs | 10. Restructuring, impairment and other costs The following table summarizes the expenses recognized in restructuring, impairment and other costs in our condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Employee severance and benefits $ 1,022 $ 57,903 $ 2,285 $ 57,903 Impairments and losses on disposals of long-lived assets, net 881,165 55,500 1,012,360 60,317 Other restructuring costs (4,898) 11,819 (3,802) 11,819 Total restructuring, impairment and other costs $ 877,289 $ 125,222 $ 1,010,843 $ 130,039 In July 2022, we initiated a strategic realignment of our operations to reduce operating costs. The strategic realignment is complete and includes a reduction in workforce, lab and office space consolidation, elimination of business activities and services, decrease in other operating expenses, as well as a reduced international footprint. Under this strategic realignment, we reduced our workforce by approximately 1,000 employees with a majority of these employees separating from the Company by September 30, 2022 and the remaining affected employees transitioned over the last 12 months. Employees who were impacted by the restructuring were eligible to receive severance benefits contingent upon an impacted employee’s execution (and non-revocation, where applicable) of a separation agreement, which included a general release of claims against us. Employee severance and benefits are comprised of severance, other termination benefit costs, and stock-based compensation expense for the acceleration of RSUs related to workforce reductions. See Note 9, "Stock incentive plans" for additional information about the accelerated vesting of RSUs. Impairments and losses on disposals of long-lived assets, net include the write-off of the remaining carrying value of developed technology intangible assets, the write-off of a tradename intangible asset, right-of-use assets, and losses on disposals of leasehold improvements associated with the exit of certain lab and office space and the related property and equipment. See Note 4, "Intangible assets, net" for additional information about the write-off of developed technology and tradename intangible assets. See Note 7, "Commitments and contingencies" under the heading "Leases" for additional information about right-of-use asset impairments. See Note 5, "Balance sheet components" for additional information about net losses on disposal of property and equipment. Other restructuring costs include professional fees in relation to restructuring activities and contract exit costs including our decision to cease the use or exploration of strategic alternatives for our developed technologies. During each of the three and nine months ended September 30, 2023, we recognized a gain of $5.5 million on extinguishment of a contractual liability as a result of a settlement agreement. The loss associated with the contractual liability was also previously recorded in ‘Other restructuring costs’. See Note 4, "Intangible assets, net" for additional information. The following table summarizes the changes in liabilities associated with our strategic realignment initiatives, including restructuring, impairment and other costs incurred and cash payments (in thousands): Employee severance and benefits Other restructuring costs Total Beginning balance $ — $ — $ — Accruals 35,237 7,405 42,642 Payments (32,974) (5,464) (38,438) Balance at December 31, 2022 2,263 1,941 4,204 Accruals 2,228 1,866 4,094 Payments (3,316) (3,010) (6,326) Balance at September 30, 2023 $ 1,175 $ 797 $ 1,972 The restructuring liabilities are included in accrued liabilities in the condensed consolidated balance sheets. We expect that substantially all of the remaining accrued restructuring liabilities will be paid in cash in 2023. The charges recognized in the roll forward of our accrued restructuring liabilities do not include items charged directly to expense for asset impairments and losses on disposals of long-lived assets, accelerated vesting of RSUs, and other periodic exit costs, as those items are not reflected in our restructuring liabilities in our condensed consolidated balance sheets. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 11. Income taxes We recorded income tax benefit of $6.2 million and $1.1 million during the three months ended September 30, 2023 and 2022, respectively, and $8.1 million and $39.6 million during the nine months ended September 30, 2023 and 2022, respectively, which was included in income tax benefit in the condensed consolidated statements of operations. The income tax benefit for the three months ended September 30, 2023 is primarily related to impairment of foreign acquired intangibles and the associated deferred tax liability which was not previously netted against deferred tax assets in the Company's presentation. The income tax benefit for the nine months ended September 30, 2023 is primarily related to a $6.5 million income tax benefit related to amortization and the impairment of foreign acquired intangibles and a $1.6 million release of federal valuation allowances as a result of the impact on our deferred taxes related to Internal Revenue Code Section 174 research and experimental expense capitalization and right-of-use asset impairments, which enabled the associated deferred tax liability to serve as a source of income to support the realization of existing deferred tax assets for which a valuation allowance had previously been established. As of September 30, 2023, we maintained $59.3 million of unrecognized tax benefits, of which $0.2 million, if recognized, would affect the Company’s effective tax rate. The remainder has been recorded as a reduction to the Company’s deferred tax assets and, if recognized, would not have an impact on the effective tax rate due to existing valuation allowance against such deferred tax assets. It is possible that the Company’s unrecognized tax benefits could change within the next twelve months due to activities of tax authorities, including possible settlement of audits, should any arise, or through normal expiration of statutes of limitations. The Company’s policy is to include penalties and interest expense related to income taxes as a component of tax expense. As of September 30, 2023, there were no accrued interest and penalties related to the unrecognized tax benefits. Effective for tax years beginning on or after January 1, 2022, pursuant to the Tax Cuts and Jobs Act of 2017, companies are required to capitalize and amortize Internal Revenue Code Section 174 research and experimental expenses paid or incurred over five years for research and development performed in the United States and 15 years for research and development performed outside of the United States. As a result of the Internal Revenue Code Section 174 research and experimental expense capitalization, the Company recognized a deferred tax asset for the future tax benefit of the amortization deductions with offsetting increase in the valuation allowance on deferred tax assets. The Inflation Reduction Act of 2022 ("IRA") was signed into law on August 16, 2022. The bill was meant to address the high inflation rate in the U.S. through various climate, energy, healthcare and other incentives. These incentives are meant to be paid for by the tax provisions included in the IRA, such as a new 15 percent corporate minimum tax, a 1 percent new excise tax on stock buybacks, additional IRS funding to improve taxpayer compliance and others. At this time, none of the IRA tax provisions are expected to have a material impact to the Company's tax provision. The Company will continue to monitor for updates to the Company's business along with guidance issued with respect to the IRA to determine whether any adjustments are needed to the Company's tax provision in future periods. |
Net loss per share
Net loss per share | 9 Months Ended |
Sep. 30, 2023 | |
Earnings Per Share [Abstract] | |
Net loss per share | 12. Net loss per share The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net loss $ (942,107) $ (301,156) $ (1,340,801) $ (3,006,476) Shares used in computing net loss per share, basic and diluted 275,604 237,974 263,210 232,889 Net loss per share, basic and diluted $ (3.42) $ (1.27) $ (5.09) $ (12.91) Common stock issuable in connection with our Convertible Senior Notes and the Senior Secured 2028 Notes participate in any dividends that may be declared by the Company and are therefore considered to be participating securities. The net losses were attributable entirely to common stockholders since the participating securities did not have a contractual obligation to share in the Company’s losses. The following common stock equivalents have been excluded from diluted net loss per share because their inclusion would be anti-dilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Shares of common stock subject to outstanding options 2,503 3,621 2,456 3,174 Shares of common stock subject to outstanding RSUs and PRSUs 16,637 18,660 15,749 18,587 Shares of common stock pursuant to ESPP 3,436 1,600 3,580 2,292 Shares of common stock subject to convertible senior notes conversion 27,543 38,403 27,543 38,403 Shares of common stock subject to convertible senior secured notes conversion 118,334 — 90,163 — Total shares of common stock equivalents 168,453 62,284 139,491 62,456 |
Geographic information
Geographic information | 9 Months Ended |
Sep. 30, 2023 | |
Segments, Geographical Areas [Abstract] | |
Geographic information | 13. Geographic information Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 United States $ 113,723 $ 117,316 $ 337,457 $ 345,721 Canada 1,886 2,099 6,276 6,567 United Kingdom 1,401 3,004 3,235 7,872 Rest of world 4,231 11,117 12,161 33,689 Total revenue $ 121,241 $ 133,536 $ 359,129 $ 393,849 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Pay vs Performance Disclosure | |||||||
Net loss | $ (942,107) | $ (301,156) | $ (1,340,801) | $ (3,006,476) | $ (3,100,000) | $ (379,000) | $ (602,200) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Sep. 30, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Summary of significant accoun_2
Summary of significant accounting policies (Policies) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of presentation | Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (including normal recurring adjustments) considered necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022. The results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results expected for the full fiscal year or any other periods. |
Principles of consolidation | Principles of consolidation Our unaudited condensed consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. |
Use of estimates | Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base these estimates on current facts, historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to |
Prior period reclassifications | Prior period reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation. L oss on disposal of property and equipment and impairment charges related to right-of-use assets and the related leasehold improvements are now included in restructuring, impairment and other costs in the condensed consolidated statements of operations. This reclassification had no effect on the previously reported results of operations. |
Concentrations of credit risk and other risks and uncertainties | Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, restricted cash, marketable securities and accounts receivable. Our cash and cash equivalents are primarily held by financial institutions in the United States. Such deposits often exceed federally insured limits. |
Fair value of financial instruments | Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued liabilities, operating and finance leases obligations, liabilities associated with business combinations, and convertible senior notes. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to us, the carrying value of our operating and finance leases approximates their fair values. Liabilities associated with business combinations and our 4.50% Series A convertible senior secured notes due 2028 (the “Series A Notes”) and 4.50% Series B convertible senior secured notes due 2028 (the “Series B Notes” and, together with the Series A Notes, the "Senior Secured 2028 Notes") are recorded at their estimated fair value. Fair value option election The fair value option provides an election that allows an entity to irrevocably elect to record certain financial assets and liabilities at fair value on an instrument-by-instrument basis at initial recognition. We have elected to apply the fair value option to the Senior Secured 2028 Notes and stock payable liabilities resulting from business combinations. The Senior Secured 2028 Notes accounted for under the fair value option election pursuant to ASC 825, Financial Instruments, are each a debt host financial instrument containing embedded features that would otherwise be required to be bifurcated from the debt-host and recognized as separate derivative liabilities subject to initial and recurring estimated fair value measurements under ASC 815, Derivatives and Hedging . Notwithstanding, ASC 825 provides for the fair value option election, to the extent not otherwise prohibited by ASC 825, to be afforded to financial instruments. When the fair value option election is applied to financial liabilities, bifurcation of an embedded derivative is not required, and the financial liability is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis as of each reporting period date. The estimated fair value adjustment related to the portion of the change in fair value attributed to a change in the instrument-specific credit risk is recognized as a component of other comprehensive loss, with the remaining amount of the fair value adjustment recognized in other income (expense), net in our condensed consolidated statements of operations. We have elected to present the component related to accrued interest in the change in fair value of the Senior Secured 2028 Notes. |
Restructuring, impairment and other costs | Restructuring, impairment and other costs Restructuring, impairment and other costs are comprised of employee severance and benefits, asset impairments and losses on asset disposals, and other costs. Employee severance and benefit costs are comprised of severance, other termination benefit costs, and stock-based compensation expense for the acceleration of stock awards related to workforce reductions. We recognize costs and liabilities associated with exit and disposal activities in accordance with ASC 420, Exit and Disposal Cost Obligations, and other costs and liabilities associated with nonretirement postemployment benefits in accordance with ASC 712, Nonretirement Postemployment Benefits . Liabilities are based on the estimate of fair value in the period the liabilities are incurred, with subsequent changes to the liability recognized as adjustments in the period of change. We recognize asset impairments and losses on disposals of long-lived assets in accordance with ASC 360, Impairment or Disposal of Long-Lived Assets . Restructuring, impairment and other costs are recognized as an operating expense within the condensed consolidated statements of operations and related liabilities are recorded within accrued liabilities in the condensed consolidated balance sheets. |
Recent accounting pronouncements | Recent accounting pronouncements We evaluate all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the "FASB") for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on our condensed consolidated financial statements. Recently adopted accounting pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations ("Topic 805"): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments of this ASU require entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers . The Company adopted the amendments in this update on January 1, 2023 with no impact to our condensed consolidated financial statements at the date of adoption. The amendments will be applied prospectively to any future business combinations. |
Summary of significant accoun_3
Summary of significant accounting policies (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Summary of restrictions on cash and cash equivalents | Cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets are reconciled to the amounts reported in the condensed consolidated statements of cash flows as follows (in thousands): September 30, 2023 September 30, 2022 Cash and cash equivalents $ 158,007 $ 217,029 Restricted cash 10,100 10,027 Total cash, cash equivalents and restricted cash $ 168,107 $ 227,056 |
Schedule of cash and cash equivalents | Cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets are reconciled to the amounts reported in the condensed consolidated statements of cash flows as follows (in thousands): September 30, 2023 September 30, 2022 Cash and cash equivalents $ 158,007 $ 217,029 Restricted cash 10,100 10,027 Total cash, cash equivalents and restricted cash $ 168,107 $ 227,056 |
Revenue, accounts receivable _2
Revenue, accounts receivable and deferred revenue (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of disaggregated revenue | The following tables present disaggregated revenue by customer and product offering by category (in thousands): Patient Institution Three Months Ended September 30, 2023 Insurance Direct Product: Oncology $ 52,903 $ 1,680 $ 7,162 $ 61,745 Women's health 22,177 3,082 1,597 26,856 Rare diseases 15,534 2,386 5,381 23,301 Data/services — — 9,339 9,339 Total revenue $ 90,614 $ 7,148 $ 23,479 $ 121,241 Patient Institution Three Months Ended September 30, 2022 Insurance Direct Product: Oncology $ 53,104 $ 2,205 $ 23,862 $ 79,171 Women's health 18,887 3,977 1,775 24,639 Rare diseases 8,493 2,577 6,085 17,155 Data/services — — 12,571 12,571 Total revenue $ 80,484 $ 8,759 $ 44,293 $ 133,536 Patient Institution Nine Months Ended September 30, 2023 Insurance Direct Product: Oncology $ 155,663 $ 5,233 $ 20,957 $ 181,853 Women's health 63,921 9,998 4,395 78,314 Rare diseases 40,880 7,337 17,173 65,390 Data/services — — 33,572 33,572 Total revenue $ 260,464 $ 22,568 $ 76,097 $ 359,129 Patient Institution Nine Months Ended September 30, 2022 Insurance Direct Product: Oncology $ 155,298 $ 8,499 $ 68,753 $ 232,550 Women's health 54,963 15,031 6,061 76,055 Rare diseases 23,093 7,806 18,990 49,889 Data/services — — 35,355 35,355 Total revenue $ 233,354 $ 31,336 $ 129,159 $ 393,849 |
Schedule of change in estimate | In subsequent periods, we update our estimate of the amounts recognized for previously delivered tests resulting in the following (decrease) increase to revenue and (decrease) increase to our net (loss) income from operations and basic and diluted net (loss) income per share (in millions, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenue $ (0.3) $ 1.1 $ (4.5) $ 3.5 (Loss) income from operations $ (0.3) $ 1.1 $ (4.5) $ 3.5 Net (loss) income per share, basic and diluted $ — $ — $ (0.02) $ 0.02 |
Intangible Assets, Net (Tables)
Intangible Assets, Net (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of intangible assets, indefinite-lived | The following table presents details of our acquired intangible assets as of September 30, 2023 (in thousands): September 30, 2023 Cost Accumulated Asset Disposals/Impairments Net Weighted-Average Customer relationships $ 40,928 $ (20,838) $ (20,090) $ — 10.8 Developed technology 1,138,702 (243,969) (894,733) — 11.1 Trade name 21,072 (5,268) (15,804) — — $ 1,200,702 $ (270,075) $ (930,627) $ — 11.1 The following table presents details of our acquired intangible assets as of December 31, 2022 (in thousands): December 31, 2022 Cost Accumulated Asset Disposals/Impairments Net Weighted-Average Customer relationships $ 41,515 $ (17,675) $ (359) $ 23,481 10.8 Developed technology 1,174,506 (183,133) (19,426) 971,947 10.8 Non-compete agreement 286 (286) — — — Trade name 21,085 (3,964) — 17,121 12.0 Patent assets and licenses 495 (156) (339) — — Right to develop new technology 19,359 (2,474) (16,885) — — $ 1,257,246 $ (207,688) $ (37,009) $ 1,012,549 10.8 |
Schedule of intangible assets, finite-lived | The following table presents details of our acquired intangible assets as of September 30, 2023 (in thousands): September 30, 2023 Cost Accumulated Asset Disposals/Impairments Net Weighted-Average Customer relationships $ 40,928 $ (20,838) $ (20,090) $ — 10.8 Developed technology 1,138,702 (243,969) (894,733) — 11.1 Trade name 21,072 (5,268) (15,804) — — $ 1,200,702 $ (270,075) $ (930,627) $ — 11.1 The following table presents details of our acquired intangible assets as of December 31, 2022 (in thousands): December 31, 2022 Cost Accumulated Asset Disposals/Impairments Net Weighted-Average Customer relationships $ 41,515 $ (17,675) $ (359) $ 23,481 10.8 Developed technology 1,174,506 (183,133) (19,426) 971,947 10.8 Non-compete agreement 286 (286) — — — Trade name 21,085 (3,964) — 17,121 12.0 Patent assets and licenses 495 (156) (339) — — Right to develop new technology 19,359 (2,474) (16,885) — — $ 1,257,246 $ (207,688) $ (37,009) $ 1,012,549 10.8 |
Balance sheet components (Table
Balance sheet components (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of inventory | Inventory consisted of the following (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 21,368 $ 29,992 Work in progress 259 382 Finished goods — 12 Total inventory $ 21,627 $ 30,386 |
Schedule of property and equipment | Property and equipment consisted of the following (in thousands): September 30, 2023 December 31, 2022 Leasehold improvements $ 56,392 $ 73,095 Laboratory equipment 50,465 67,261 Computer equipment 11,147 13,511 Furniture and fixtures 996 1,427 Construction-in-progress 7,621 21,006 Other 8,110 2,996 Total property and equipment, gross 134,731 179,296 Accumulated depreciation (69,285) (70,573) Total property and equipment, net $ 65,446 $ 108,723 |
Schedule of accrued liabilities | Accrued liabilities consisted of the following (in thousands): September 30, 2023 December 31, 2022 Accrued compensation and related expenses $ 39,345 $ 25,315 Accrued litigation expense 20,761 905 Accrued expenses 14,349 23,628 Deferred revenue 4,788 4,814 Other accrued liabilities 3,265 4,568 Accrued royalties 2,176 3,177 Accrued interest 45 6,646 Compensation and other liabilities associated with business combinations — 5,335 Total accrued liabilities $ 84,729 $ 74,388 |
Fair value measurements (Tables
Fair value measurements (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Financial instruments at fair value on a recurring basis | The following tables set forth the fair value of our financial instruments that were measured at fair value on a recurring basis (in thousands): September 30, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Level 1 Level 2 Level 3 Financial assets: Money market funds $ 163,424 $ — $ — $ 163,424 $ 163,424 $ — $ — U.S. Treasury notes 18,848 — (1) 18,847 18,847 — — U.S. government agency securities 77,707 19 (7) 77,719 — 77,719 — Total financial assets $ 259,979 $ 19 $ (8) $ 259,990 $ 182,271 $ 77,719 $ — Financial liabilities: Convertible senior secured notes $ 196,244 $ — $ — $ 196,244 Contingent consideration 25 — — 25 Total financial liabilities $ 196,269 $ — $ — $ 196,269 September 30, 2023 Reported as: Cash equivalents $ 153,324 Restricted cash 10,100 Marketable securities 96,566 Total cash equivalents, restricted cash, and marketable securities $ 259,990 Convertible senior secured notes $ 196,244 Other long-term liabilities 25 Total liabilities $ 196,269 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Level 1 Level 2 Level 3 Financial assets: Money market funds $ 158,931 $ — $ — $ 158,931 $ 158,931 $ — $ — U.S. Treasury notes 193,685 1 (123) 193,563 193,563 — — U.S. government agency securities 96,006 55 (13) 96,048 — 96,048 — Total financial assets $ 448,622 $ 56 $ (136) $ 448,542 $ 352,494 $ 96,048 $ — Financial liabilities: Stock payable liability $ 744 $ — $ — $ 744 Contingent consideration 25 — — 25 Total financial liabilities $ 769 $ — $ — $ 769 December 31, 2022 Reported as: Cash equivalents $ 148,901 Restricted cash 10,030 Marketable securities 289,611 Total cash equivalents, restricted cash, and marketable securities $ 448,542 Other long-term liabilities $ 769 |
Rollforward of stock payable liability and contingent consideration | The following tables include a rollforward of the stock payable liability, contingent consideration, and Senior Secured 2028 Notes classified within Level 3 of the fair value hierarchy (in thousands): Three Months Ended September 30, 2023 Stock Payable Liability Contingent Consideration Convertible Senior Secured Notes Fair value at June 30, 2023 $ 251 $ 25 $ 249,571 Issuance of convertible senior secured notes at fair value — — 100 Changes in fair value (70) — (33,463) Changes in fair value related to instrument-specific credit risk — — (16,529) Settlements (181) — — Cash payments for interest — — (3,435) Fair value at September 30, 2023 $ — $ 25 $ 196,244 Nine Months Ended September 30, 2023 Stock Payable Liability Contingent Consideration Convertible Senior Secured Notes Fair value at December 31, 2022 $ 744 $ 25 $ — Issuance of convertible senior secured notes at fair value — — 301,171 Changes in fair value (337) — (72,386) Changes in fair value related to instrument-specific credit risk — — (25,366) Settlements (407) — — Cash payments for interest — — (7,175) Fair value at September 30, 2023 $ — $ 25 $ 196,244 Three Months Ended Stock Payable Liability Contingent Consideration Fair value at June 30, 2022 $ 2,782 $ 25 Change in fair value 527 — Settlements (2,324) — Fair value at September 30, 2022 $ 985 $ 25 Nine Months Ended Stock Payable Liability Contingent Consideration Fair value at December 31, 2021 $ 20,925 $ 1,875 Change in fair value (15,666) (1,850) Settlements (4,274) — Fair value at September 30, 2022 $ 985 $ 25 |
Summary of significant inputs in the binomial lattice model | Significant inputs into the binomial lattice model as of September 30, 2023 and March 7, 2023 were as follows: September 30, 2023 March 7, 2023 Stock price $0.61 $1.65 Conversion price $2.58 $2.58 Volatility 110.0 % 107.5 % Risk-free interest rate 4.71 % 4.35 % Credit spread 17.92 % 13.76 % Cost of debt 22.6 % 18.1 % Term (years) 4.46 5.02 |
Commitments and contingencies (
Commitments and contingencies (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Components of debt | Our 2024 Notes and 2028 Notes (collectively, our "Convertible Senior Notes") consisted of the following (in thousands): September 30, 2023 December 31, 2022 Outstanding principal $ 1,177,058 $ 1,499,996 Unamortized debt discount and issuance costs (22,321) (29,213) Net carrying amount $ 1,154,737 $ 1,470,783 |
Stockholders' equity (Tables)
Stockholders' equity (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Schedule of convertible preferred and common stock | Shares of common stock were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Common stock: Shares outstanding, beginning of period 266,762 234,767 245,562 228,116 Common stock issued in connection with the convertible senior notes exchange 15,820 — 30,040 — Common stock issued in connection with public offering 50 2,429 50 2,429 Common stock issued on exercise of stock options, net — 17 2 150 Common stock issued pursuant to vesting of RSUs 3,408 4,645 8,374 9,401 Common stock issued pursuant to employee stock purchase plan — — 1,835 1,535 Common stock issued pursuant to acquisitions 453 972 630 1,199 Shares outstanding, end of period 286,493 242,830 286,493 242,830 |
Stock incentive plans (Tables)
Stock incentive plans (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of activity under the plans | Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share data and years): Shares Available For Grant Stock Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balances at December 31, 2022 12,625 2,541 $ 8.49 6.6 $ 16 Additional shares reserved 9,822 — Options granted (325) 325 1.46 Options cancelled 381 (381) 9.25 Options exercised — (2) 0.86 RSUs and PRSUs granted (17,448) — RSUs and PRSUs cancelled 2,835 — Balances at September 30, 2023 7,890 2,483 $ 7.46 6.7 $ — Options exercisable at September 30, 2023 1,498 $ 9.78 5.2 $ — Options vested and expected to vest at September 30, 2023 2,335 $ 7.76 6.5 $ — |
Summary of RSU activity | The following table summarizes RSU, including PRSU, activity (in thousands, except per share data): Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2022 11,895 $ 11.70 RSUs granted 17,448 $ 1.12 RSUs vested (8,374) $ 13.81 RSUs cancelled (2,835) $ 7.02 Balance at September 30, 2023 18,134 $ 1.28 |
Summary of stock based compensation expense | The following table summarizes stock-based compensation expense included in the condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of revenue $ 755 $ 1,203 $ 2,791 $ 5,702 Research and development 19,081 24,301 58,800 94,661 Selling and marketing 1,354 2,625 6,245 10,498 General and administrative 4,755 7,477 17,661 28,646 Restructuring, impairment and other costs 52 24,807 57 24,807 Total stock-based compensation expense $ 25,997 $ 60,413 $ 85,554 $ 164,314 |
Restructuring, impairment and_2
Restructuring, impairment and other costs (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Related Costs | The following table summarizes the expenses recognized in restructuring, impairment and other costs in our condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Employee severance and benefits $ 1,022 $ 57,903 $ 2,285 $ 57,903 Impairments and losses on disposals of long-lived assets, net 881,165 55,500 1,012,360 60,317 Other restructuring costs (4,898) 11,819 (3,802) 11,819 Total restructuring, impairment and other costs $ 877,289 $ 125,222 $ 1,010,843 $ 130,039 The following table summarizes the changes in liabilities associated with our strategic realignment initiatives, including restructuring, impairment and other costs incurred and cash payments (in thousands): Employee severance and benefits Other restructuring costs Total Beginning balance $ — $ — $ — Accruals 35,237 7,405 42,642 Payments (32,974) (5,464) (38,438) Balance at December 31, 2022 2,263 1,941 4,204 Accruals 2,228 1,866 4,094 Payments (3,316) (3,010) (6,326) Balance at September 30, 2023 $ 1,175 $ 797 $ 1,972 |
Net loss per share (Tables)
Net loss per share (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of earnings per share, basic and diluted | The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net loss $ (942,107) $ (301,156) $ (1,340,801) $ (3,006,476) Shares used in computing net loss per share, basic and diluted 275,604 237,974 263,210 232,889 Net loss per share, basic and diluted $ (3.42) $ (1.27) $ (5.09) $ (12.91) |
Schedule of antidilutive securities excluded from computation of earnings per share | The following common stock equivalents have been excluded from diluted net loss per share because their inclusion would be anti-dilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Shares of common stock subject to outstanding options 2,503 3,621 2,456 3,174 Shares of common stock subject to outstanding RSUs and PRSUs 16,637 18,660 15,749 18,587 Shares of common stock pursuant to ESPP 3,436 1,600 3,580 2,292 Shares of common stock subject to convertible senior notes conversion 27,543 38,403 27,543 38,403 Shares of common stock subject to convertible senior secured notes conversion 118,334 — 90,163 — Total shares of common stock equivalents 168,453 62,284 139,491 62,456 |
Geographic information (Tables)
Geographic information (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Segments, Geographical Areas [Abstract] | |
Schedule of revenue by country | Revenue by country is determined based on the billing address of the customer and is summarized as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 United States $ 113,723 $ 117,316 $ 337,457 $ 345,721 Canada 1,886 2,099 6,276 6,567 United Kingdom 1,401 3,004 3,235 7,872 Rest of world 4,231 11,117 12,161 33,689 Total revenue $ 121,241 $ 133,536 $ 359,129 $ 393,849 |
Organization and description _2
Organization and description of business (Details) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) Segment | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||||
Number of operating segments | Segment | 1 | |||||||
Accumulated deficit | $ (6,169,942) | $ (6,169,942) | $ (4,829,141) | |||||
Net loss | (942,107) | $ (301,156) | (1,340,801) | $ (3,006,476) | (3,100,000) | $ (379,000) | $ (602,200) | |
Net cash used in operating activities | 156,198 | 410,934 | 493,000 | $ 559,800 | $ 298,500 | |||
Impairments and losses on disposals of long-lived assets, net | 881,165 | $ 55,500 | 1,012,360 | 60,317 | ||||
Goodwill, impairment loss | $ 2,300,000 | |||||||
Intangible asset impairment | $ 30,000 | $ 60,300 | ||||||
Cash, cash equivalents, and marketable securities | $ 254,600 | $ 254,600 | $ 547,100 |
Summary of significant accoun_4
Summary of significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Dec. 31, 2021 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 158,007 | $ 257,489 | $ 217,029 | |
Restricted cash | 10,100 | 10,030 | 10,027 | |
Total cash, cash equivalents and restricted cash | $ 168,107 | $ 267,519 | $ 227,056 | $ 933,525 |
Summary of significant accoun_5
Summary of significant accounting policies - Narrative (Details) - Convertible Senior Secured Notes | Feb. 28, 2023 |
Series A Notes | |
Debt Instrument [Line Items] | |
Stated interest rate | 4.50% |
Series B Notes | |
Debt Instrument [Line Items] | |
Stated interest rate | 4.50% |
Revenue, accounts receivable _3
Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Disaggregation of Revenue [Line Items] | ||||
Total revenue | $ 121,241 | $ 133,536 | $ 359,129 | $ 393,849 |
Patient Insurance | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 90,614 | 80,484 | 260,464 | 233,354 |
Patient Direct | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 7,148 | 8,759 | 22,568 | 31,336 |
Institution | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 23,479 | 44,293 | 76,097 | 129,159 |
Oncology | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 61,745 | 79,171 | 181,853 | 232,550 |
Oncology | Patient Insurance | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 52,903 | 53,104 | 155,663 | 155,298 |
Oncology | Patient Direct | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 1,680 | 2,205 | 5,233 | 8,499 |
Oncology | Institution | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 7,162 | 23,862 | 20,957 | 68,753 |
Women's health | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 26,856 | 24,639 | 78,314 | 76,055 |
Women's health | Patient Insurance | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 22,177 | 18,887 | 63,921 | 54,963 |
Women's health | Patient Direct | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 3,082 | 3,977 | 9,998 | 15,031 |
Women's health | Institution | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 1,597 | 1,775 | 4,395 | 6,061 |
Rare diseases | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 23,301 | 17,155 | 65,390 | 49,889 |
Rare diseases | Patient Insurance | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 15,534 | 8,493 | 40,880 | 23,093 |
Rare diseases | Patient Direct | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 2,386 | 2,577 | 7,337 | 7,806 |
Rare diseases | Institution | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 5,381 | 6,085 | 17,173 | 18,990 |
Data/services | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 9,339 | 12,571 | 33,572 | 35,355 |
Data/services | Patient Insurance | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Data/services | Patient Direct | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | 0 | 0 | 0 | 0 |
Data/services | Institution | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenue | $ 9,339 | $ 12,571 | $ 33,572 | $ 35,355 |
Revenue, accounts receivable _4
Revenue, accounts receivable and deferred revenue - Schedule of change in estimate (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||
Total revenue | $ 121,241 | $ 133,536 | $ 359,129 | $ 393,849 |
(Loss) income from operations | 980,188 | 289,951 | 1,382,021 | 3,023,515 |
Change in estimate of revenue recognition | ||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||
Total revenue | (300) | 1,100 | (4,500) | 3,500 |
(Loss) income from operations | $ (300) | $ 1,100 | $ (4,500) | $ 3,500 |
Net loss per share, basic (in dollars per share) | $ 0 | $ 0 | $ (0.02) | $ 0.02 |
Net loss per share, diluted (in dollars per share) | $ 0 | $ 0 | $ (0.02) | $ 0.02 |
Revenue, accounts receivable _5
Revenue, accounts receivable and deferred revenue - Additional information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2023 | Dec. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |||
Contract receivable | $ 1,800 | $ 1,800 | $ 1,300 |
Deferred revenue, revenue recognized | 1,900 | 2,300 | |
Deferred revenue | 4,788 | 4,788 | 4,814 |
Long-term contract liability | 0 | 0 | 100 |
Refund liability | $ 1,600 | $ 1,600 | $ 4,700 |
Performance obligation timing | one to six months |
Intangible Assets, Net - Schedu
Intangible Assets, Net - Schedule of intangible assets (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] | ||
Accumulated Amortization | $ (270,075) | $ (207,688) |
Asset Disposals/Impairments | $ (930,627) | $ (37,009) |
Weighted-Average Useful Life (In Years) | 11 years 1 month 6 days | 10 years 9 months 18 days |
Cost | $ 1,200,702 | $ 1,257,246 |
Net | 0 | 1,012,549 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 40,928 | 41,515 |
Accumulated Amortization | (20,838) | (17,675) |
Asset Disposals/Impairments | (20,090) | (359) |
Net | $ 0 | $ 23,481 |
Weighted-Average Useful Life (In Years) | 10 years 9 months 18 days | 10 years 9 months 18 days |
Developed technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $ 1,138,702 | $ 1,174,506 |
Accumulated Amortization | (243,969) | (183,133) |
Asset Disposals/Impairments | (894,733) | (19,426) |
Net | $ 0 | $ 971,947 |
Weighted-Average Useful Life (In Years) | 11 years 1 month 6 days | 10 years 9 months 18 days |
Trade name | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $ 21,072 | $ 21,085 |
Accumulated Amortization | (5,268) | (3,964) |
Asset Disposals/Impairments | (15,804) | 0 |
Net | $ 0 | $ 17,121 |
Weighted-Average Useful Life (In Years) | 0 years | 12 years |
Non-compete agreement | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $ 286 | |
Accumulated Amortization | (286) | |
Asset Disposals/Impairments | 0 | |
Net | $ 0 | |
Weighted-Average Useful Life (In Years) | 0 years | |
Patent assets and licenses | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $ 495 | |
Accumulated Amortization | (156) | |
Asset Disposals/Impairments | (339) | |
Net | $ 0 | |
Weighted-Average Useful Life (In Years) | 0 years | |
Right to develop new technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $ 19,359 | |
Accumulated Amortization | (2,474) | |
Asset Disposals/Impairments | (16,885) | |
Net | $ 0 | |
Weighted-Average Useful Life (In Years) | 0 years |
Intangible Assets, Net - Additi
Intangible Assets, Net - Additional information (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||||
Amortization expense | $ 25.6 | $ 29.6 | $ 81.9 | $ 79.8 |
Intangible Assets, Net - Impair
Intangible Assets, Net - Impairment Assessment (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Finite-Lived Intangible Assets [Line Items] | |||||||
Goodwill, impairment loss | $ 2,300,000 | ||||||
Intangible asset impairment | 30,000 | $ 60,300 | |||||
Loss on disposal of property and equipment | $ 21,600 | $ 8,500 | $ 4,800 | ||||
Impairment of intangible assets | 788,700 | $ 788,700 | |||||
Other restructuring costs | (4,898) | $ 11,819 | (3,802) | $ 11,819 | |||
Contract Termination | |||||||
Finite-Lived Intangible Assets [Line Items] | |||||||
Other restructuring costs | $ 1,000 | ||||||
Developed technology | |||||||
Finite-Lived Intangible Assets [Line Items] | |||||||
Impairment of intangible assets | $ 74,800 | $ 2,100 | |||||
Pharmacogenetic Testing | |||||||
Finite-Lived Intangible Assets [Line Items] | |||||||
Impairment of intangible assets | 43,700 | $ 5,500 | |||||
Trade name | |||||||
Finite-Lived Intangible Assets [Line Items] | |||||||
Impairment of intangible assets | $ 15,800 |
Balance sheet components - Sche
Balance sheet components - Schedule of inventory (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Offsetting [Abstract] | ||
Raw materials | $ 21,368 | $ 29,992 |
Work in progress | 259 | 382 |
Finished goods | 0 | 12 |
Total inventory | $ 21,627 | $ 30,386 |
Balance sheet components - Sc_2
Balance sheet components - Schedule of property and equipment (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Property and equipment | ||
Total property and equipment, gross | $ 134,731 | $ 179,296 |
Accumulated depreciation | (69,285) | (70,573) |
Total property and equipment, net | 65,446 | 108,723 |
Leasehold improvements | ||
Property and equipment | ||
Total property and equipment, gross | 56,392 | 73,095 |
Laboratory equipment | ||
Property and equipment | ||
Total property and equipment, gross | 50,465 | 67,261 |
Computer equipment | ||
Property and equipment | ||
Total property and equipment, gross | 11,147 | 13,511 |
Furniture and fixtures | ||
Property and equipment | ||
Total property and equipment, gross | 996 | 1,427 |
Construction-in-progress | ||
Property and equipment | ||
Total property and equipment, gross | 7,621 | 21,006 |
Other | ||
Property and equipment | ||
Total property and equipment, gross | $ 8,110 | $ 2,996 |
Balance sheet components - Addi
Balance sheet components - Additional information (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Balance Sheet Related Disclosures [Abstract] | |||||||
Inventory write-off | $ 0.7 | ||||||
Depreciation | $ 5.2 | $ 9.7 | $ 15.6 | $ 21.1 | |||
Loss on disposal of property and equipment | $ 21.6 | $ 8.5 | $ 4.8 |
Balance sheet components - Sc_3
Balance sheet components - Schedule of accrued liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Balance Sheet Related Disclosures [Abstract] | ||
Accrued compensation and related expenses | $ 39,345 | $ 25,315 |
Accrued litigation expense | 20,761 | 905 |
Accrued expenses | 14,349 | 23,628 |
Deferred revenue | 4,788 | 4,814 |
Other accrued liabilities | 3,265 | 4,568 |
Accrued royalties | 2,176 | 3,177 |
Accrued interest | 45 | 6,646 |
Compensation and other liabilities associated with business combinations | 0 | 5,335 |
Total accrued liabilities | $ 84,729 | $ 74,388 |
Fair value measurements - Finan
Fair value measurements - Financial instruments at fair value on a recurring basis (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 | Sep. 30, 2022 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Amortized Cost | $ 259,979 | $ 448,622 | |
Gross Unrealized Gains | 19 | 56 | |
Gross Unrealized Losses | (8) | (136) | |
Financial assets: | 259,990 | 448,542 | |
Convertible senior secured notes, current portion | 196,244 | ||
Other long-term liabilities | 25 | 769 | |
Total financial liabilities | 196,269 | ||
Cash equivalents | 153,324 | 148,901 | |
Restricted cash | 10,100 | 10,030 | $ 10,027 |
Marketable securities | 96,566 | 289,611 | |
Recurring basis | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial assets | 259,990 | 448,542 | |
Convertible senior secured notes, current portion | 196,244 | ||
Total financial liabilities | 196,269 | 769 | |
Recurring basis | Level 1 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial assets | 182,271 | 352,494 | |
Convertible senior secured notes, current portion | 0 | ||
Total financial liabilities | 0 | 0 | |
Recurring basis | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial assets | 77,719 | 96,048 | |
Convertible senior secured notes, current portion | 0 | ||
Total financial liabilities | 0 | 0 | |
Recurring basis | Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial assets | 0 | 0 | |
Convertible senior secured notes, current portion | 196,244 | ||
Total financial liabilities | 196,269 | 769 | |
Money market funds | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Amortized Cost | 163,424 | 158,931 | |
Gross Unrealized Gains | 0 | 0 | |
Gross Unrealized Losses | 0 | 0 | |
Money market funds | Recurring basis | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 163,424 | 158,931 | |
Money market funds | Recurring basis | Level 1 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 163,424 | 158,931 | |
Money market funds | Recurring basis | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 0 | 0 | |
Money market funds | Recurring basis | Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 0 | 0 | |
U.S. Treasury notes | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Amortized Cost | 18,848 | 193,685 | |
Gross Unrealized Gains | 0 | 1 | |
Gross Unrealized Losses | (1) | (123) | |
U.S. Treasury notes | Recurring basis | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 18,847 | 193,563 | |
U.S. Treasury notes | Recurring basis | Level 1 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 18,847 | 193,563 | |
U.S. Treasury notes | Recurring basis | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 0 | 0 | |
U.S. Treasury notes | Recurring basis | Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 0 | 0 | |
U.S. government agency securities | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Amortized Cost | 77,707 | 96,006 | |
Gross Unrealized Gains | 19 | 55 | |
Gross Unrealized Losses | (7) | (13) | |
U.S. government agency securities | Recurring basis | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 77,719 | 96,048 | |
U.S. government agency securities | Recurring basis | Level 1 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 0 | 0 | |
U.S. government agency securities | Recurring basis | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 77,719 | 96,048 | |
U.S. government agency securities | Recurring basis | Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Financial assets: | 0 | 0 | |
Stock payable liability | Recurring basis | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial liabilities | 744 | ||
Stock payable liability | Recurring basis | Level 1 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial liabilities | 0 | ||
Stock payable liability | Recurring basis | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial liabilities | 0 | ||
Stock payable liability | Recurring basis | Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial liabilities | 744 | ||
Contingent consideration | Recurring basis | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial liabilities | 25 | 25 | |
Contingent consideration | Recurring basis | Level 1 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial liabilities | 0 | 0 | |
Contingent consideration | Recurring basis | Level 2 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial liabilities | 0 | 0 | |
Contingent consideration | Recurring basis | Level 3 | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Total financial liabilities | $ 25 | $ 25 |
Fair value measurements - Rollf
Fair value measurements - Rollforward of liabilities at fair value (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Stock Payable Liability | ||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Fair value, beginning balance | $ 251 | $ 2,782 | $ 744 | $ 20,925 |
Issuance of convertible senior secured notes at fair value | 0 | 0 | ||
Change in fair value, income (expense) | 70 | 527 | 337 | 15,666 |
Changes in fair value related to instrument-specific credit risk | 0 | 0 | ||
Settlements | (181) | (2,324) | (407) | (4,274) |
Cash payments for interest | 0 | 0 | ||
Fair value, ending balance | 0 | 985 | 0 | 985 |
Contingent consideration | ||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Fair value, beginning balance | 25 | 25 | 25 | 1,875 |
Issuance of convertible senior secured notes at fair value | 0 | 0 | ||
Change in fair value, income (expense) | 0 | 0 | 0 | 1,850 |
Changes in fair value related to instrument-specific credit risk | 0 | 0 | ||
Settlements | 0 | 0 | 0 | 0 |
Cash payments for interest | 0 | 0 | ||
Fair value, ending balance | 25 | $ 25 | 25 | $ 25 |
Convertible Senior Secured Notes | ||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Fair value, beginning balance | 249,571 | 0 | ||
Issuance of convertible senior secured notes at fair value | 100 | 301,171 | ||
Change in fair value, income (expense) | 33,463 | 72,386 | ||
Changes in fair value related to instrument-specific credit risk | (16,529) | (25,366) | ||
Settlements | 0 | 0 | ||
Cash payments for interest | (3,435) | (7,175) | ||
Fair value, ending balance | $ 196,244 | $ 196,244 |
Fair value measurements - Addit
Fair value measurements - Additional information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||||
Feb. 28, 2023 | Apr. 30, 2020 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Aug. 31, 2023 | Mar. 31, 2023 | Mar. 07, 2023 | Dec. 31, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Transfers of assets and liabilities between Level 1, Level 2 and Level 3 | $ 0 | $ 0 | $ 0 | |||||||
Interest income | 2,200,000 | $ 2,000,000 | 6,500,000 | $ 5,000,000 | ||||||
Fair value of investments with unrealized losses | 36,100,000 | |||||||||
Convertible senior secured notes, current portion | 196,244,000 | 196,244,000 | ||||||||
Convertible Senior Secured Notes | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Change in fair value, income (expense) | 33,463,000 | 72,386,000 | ||||||||
Changes in fair value related to instrument-specific credit risk | 16,529,000 | 25,366,000 | ||||||||
Stock Payable Liability | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Change in fair value, income (expense) | 70,000 | 527,000 | 337,000 | 15,666,000 | ||||||
Change in fair value, income (expense) | 400,000 | |||||||||
Changes in fair value related to instrument-specific credit risk | 0 | 0 | ||||||||
Series A Notes | Convertible Senior Secured Notes | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Aggregate principal amount | $ 100,000 | $ 275,300,000 | ||||||||
Series B Notes | Convertible Senior Secured Notes | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Aggregate principal amount | $ 30,000,000 | |||||||||
Convertible Senior Secured Notes Due in 2028 | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Convertible senior secured notes, current portion | $ 301,100,000 | |||||||||
Convertible Senior Secured Notes Due in 2028 | Convertible Senior Secured Notes | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Aggregate principal amount | $ 275,300,000 | $ 100,000 | ||||||||
Proceeds from issuance of debt | $ 30,000,000 | |||||||||
Genelex | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Business acquisition, expected milestone duration | 4 years | |||||||||
Change in fair value of contingent consideration | $ 0 | $ 0 | $ 0 | $ (1,800,000) | ||||||
Minimum | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Remaining contractual maturities | 1 year | |||||||||
Maximum | ||||||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||||||
Remaining contractual maturities | 5 months |
Fair value measurements - Summa
Fair value measurements - Summary of significant inputs in the binomial lattice model (Details) | Sep. 30, 2023 | Mar. 07, 2023 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Term (years) | 4 years 5 months 15 days | 5 years 7 days |
Level 3 | Stock price | Valuation Technique Bionomial Lattice Model | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Measurement input | 0.61 | 1.65 |
Level 3 | Conversion price | Valuation Technique Bionomial Lattice Model | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Measurement input | 2.58 | 2.58 |
Level 3 | Volatility | Valuation Technique Bionomial Lattice Model | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Measurement input | 1.100 | 1.075 |
Level 3 | Risk-free interest rate | Valuation Technique Bionomial Lattice Model | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Measurement input | 0.0471 | 0.0435 |
Level 3 | Credit spread | Valuation Technique Bionomial Lattice Model | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Measurement input | 0.1792 | 0.1376 |
Level 3 | Cost of debt | Valuation Technique Bionomial Lattice Model | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Measurement input | 0.226 | 0.181 |
Commitments and contingencies -
Commitments and contingencies - Leases (Details) $ in Millions | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2023 USD ($) | Jun. 30, 2023 USD ($) | Mar. 31, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | |
Operating Leased Assets [Line Items] | ||||||
Finance lease, term of contract | 3 years | 3 years | ||||
Finance lease, impairment loss | $ 0.8 | |||||
Sublease income | 0.4 | $ 0 | $ 1.1 | $ 0 | ||
Exited Leased Premises | ||||||
Operating Leased Assets [Line Items] | ||||||
Impairment charge | 0.6 | $ 37.8 | ||||
Impairment of leasehold improvements | 2 | |||||
Leases Previously Impaired | ||||||
Operating Leased Assets [Line Items] | ||||||
Impairment charge | 9.9 | $ 0.6 | $ 2.3 | |||
Impairment of leasehold improvements | $ 17.1 | |||||
Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Leases Previously Impaired | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 0.075 | 0.0775 | 0.075 | |||
Measurement Input, Expected Sublease Income | Valuation Technique, Discounted Cash Flow | Leases Previously Impaired | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 50.9 | 50.9 | ||||
Minimum | ||||||
Operating Leased Assets [Line Items] | ||||||
Remaining lease term | 1 year | 1 year | ||||
Minimum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Exited Leased Premises | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 0.0750 | 0.070 | 0.0750 | |||
Minimum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Leases Previously Impaired | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 0.0750 | |||||
Minimum | Measurement Input, Expected Sublease Income | Valuation Technique, Discounted Cash Flow | Exited Leased Premises | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 0.1 | 7.6 | 0.1 | |||
Minimum | Measurement Input, Expected Sublease Income | Valuation Technique, Discounted Cash Flow | Leases Previously Impaired | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 0.1 | 0.3 | ||||
Maximum | ||||||
Operating Leased Assets [Line Items] | ||||||
Remaining lease term | 12 years | 12 years | ||||
Maximum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Exited Leased Premises | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 0.0775 | 0.080 | 0.0775 | |||
Maximum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Leases Previously Impaired | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 0.0775 | |||||
Maximum | Measurement Input, Expected Sublease Income | Valuation Technique, Discounted Cash Flow | Exited Leased Premises | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 33.6 | 35.7 | 33.6 | |||
Maximum | Measurement Input, Expected Sublease Income | Valuation Technique, Discounted Cash Flow | Leases Previously Impaired | ||||||
Operating Leased Assets [Line Items] | ||||||
Measurement input | 0.4 | 1.9 |
Commitments and contingencies_2
Commitments and contingencies - Debt financing (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||
Feb. 28, 2023 | Oct. 31, 2020 | Sep. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Sep. 30, 2019 | |
Long-term Purchase Commitment [Line Items] | |||||||||
Loss on extinguishment of debt | $ (229,000) | $ 0 | $ 10,593,000 | $ 0 | |||||
Payments for debt issuance costs and prepayment fees | 25,974,000 | 0 | |||||||
Convertible Senior Secured Notes | |||||||||
Long-term Purchase Commitment [Line Items] | |||||||||
Debt discounts and issuance costs | 22,321,000 | 22,321,000 | $ 29,213,000 | ||||||
Interest expense | 5,700,000 | 7,700,000 | 18,700,000 | 23,100,000 | |||||
2020 Term Loan | Secured Debt | |||||||||
Long-term Purchase Commitment [Line Items] | |||||||||
Aggregate principal amount | $ 135,000,000 | ||||||||
Debt discounts and issuance costs | $ 32,800,000 | ||||||||
Interest expense | $ 0 | $ 6,000,000 | $ 4,100,000 | $ 17,800,000 | |||||
2020 Term Loan | Secured Debt | Maximum | |||||||||
Long-term Purchase Commitment [Line Items] | |||||||||
Prepayment fee percent | 6% | ||||||||
2020 Term Loan | Secured Debt | Minimum | |||||||||
Long-term Purchase Commitment [Line Items] | |||||||||
Prepayment fee percent | 4% | ||||||||
2020 Term Loan | Secured Debt | LIBOR | |||||||||
Long-term Purchase Commitment [Line Items] | |||||||||
Floor rate | 2% | ||||||||
Basis spread on variable rate | 8.75% | ||||||||
2020 Term Loan | Convertible Senior Secured Notes | |||||||||
Long-term Purchase Commitment [Line Items] | |||||||||
Repayment of term loan | $ 135,000,000 | ||||||||
Payment of accrued interest | 2,600,000 | ||||||||
Loss on extinguishment of debt | $ 19,300,000 | ||||||||
Write-off of unamortized debt issuance costs | 11,200,000 | ||||||||
Payments for debt issuance costs and prepayment fees | 8,100,000 | ||||||||
2024 Notes | Convertible Senior Secured Notes | |||||||||
Long-term Purchase Commitment [Line Items] | |||||||||
Aggregate principal amount | $ 305,700,000 | $ 350,000,000 | |||||||
Loss on extinguishment of debt | $ (8,500,000) |
Commitments and contingencies_3
Commitments and contingencies - Convertible senior notes (Details) | 1 Months Ended | 3 Months Ended | ||||
Aug. 31, 2023 USD ($) shares | Feb. 28, 2023 USD ($) tradingDay $ / shares shares | Apr. 30, 2021 USD ($) tradingDay $ / shares | Sep. 30, 2019 USD ($) tradingDay $ / shares | Sep. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
Debt Instrument [Line Items] | ||||||
Convertible shares issued (in shares) | shares | 15,819,604 | 14,219,859 | ||||
Convertible Senior Secured Notes | ||||||
Debt Instrument [Line Items] | ||||||
Long-term debt | $ | $ 1,154,737,000 | $ 1,470,783,000 | ||||
2024 Notes | Convertible Senior Secured Notes | ||||||
Debt Instrument [Line Items] | ||||||
Aggregate principal amount | $ | $ 305,700,000 | $ 350,000,000 | ||||
Stated interest rate | 2% | |||||
Conversion price (in dollars per share) | $ / shares | $ 29.74 | |||||
Redemption price percentage | 100% | |||||
Number of threshold trading days | 20 | |||||
Number of consecutive trading days | (30) | |||||
Threshold percentage of stock price trigger | 130% | |||||
Threshold trading days immediately after five consecutive trading days | 5 | |||||
Maximum threshold percentage of stock price trigger | 98% | |||||
Threshold trading days | 30 | |||||
Long-term debt | $ | $ 27,100,000 | |||||
Conversion ratio | 0.0336293 | |||||
Convertible Senior Secured Notes | Convertible Senior Secured Notes | ||||||
Debt Instrument [Line Items] | ||||||
Aggregate principal amount | $ | $ 1,150,000,000 | |||||
Stated interest rate | 1.50% | |||||
Conversion price (in dollars per share) | $ / shares | $ 43.18 | |||||
Redemption price percentage | 100% | |||||
Number of threshold trading days | 20 | |||||
Number of consecutive trading days | (30) | |||||
Threshold percentage of stock price trigger | 150% | |||||
Percent of par value | 99% | |||||
Conversion ratio | 0.0231589 | |||||
Convertible Senior Secured Notes Due in 2028 | Convertible Senior Secured Notes | ||||||
Debt Instrument [Line Items] | ||||||
Aggregate principal amount | $ | $ 100,000 | 275,300,000 | ||||
Proceeds from issuance of debt | $ | $ 30,000,000 | |||||
Stated interest rate | 4.50% | |||||
Conversion price (in dollars per share) | $ / shares | $ 2.58 | |||||
Redemption price percentage | 100% | |||||
Threshold trading days | 60 |
Commitments and contingencies_4
Commitments and contingencies - Components of debt (Details) - Convertible Senior Secured Notes - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | ||
Outstanding principal | $ 1,177,058 | $ 1,499,996 |
Unamortized debt discount and issuance costs | (22,321) | (29,213) |
Net carrying amount | $ 1,154,737 | $ 1,470,783 |
Commitments and contingencies_5
Commitments and contingencies - Convertible senior secured notes (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||||
Aug. 31, 2023 USD ($) shares | Feb. 28, 2023 USD ($) shares tradingDay $ / shares | Apr. 30, 2021 USD ($) tradingDay $ / shares | Sep. 30, 2019 USD ($) tradingDay $ / shares | Sep. 30, 2023 USD ($) | Mar. 31, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Mar. 07, 2023 USD ($) | |
Debt Instrument [Line Items] | ||||||||||
Exchange of notes | $ 320,039,000 | $ 0 | ||||||||
Convertible shares issued (in shares) | shares | 15,819,604 | 14,219,859 | ||||||||
Gain (loss) on extinguishment of debt, net | $ 229,000 | $ 0 | (10,593,000) | 0 | ||||||
Convertible senior secured notes, current portion | 196,244,000 | 196,244,000 | ||||||||
Debt issuance costs | 845,000 | 0 | 20,704,000 | 0 | ||||||
Convertible Senior Secured Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Change in fair value, income (expense) | 33,463,000 | 72,386,000 | ||||||||
Changes in fair value related to instrument-specific credit risk | (16,529,000) | (25,366,000) | ||||||||
Convertible Senior Secured Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Interest expense | 5,700,000 | 7,700,000 | 18,700,000 | 23,100,000 | ||||||
Debt issuance costs | 1,300,000 | $ 1,700,000 | 4,000,000 | $ 5,000,000 | ||||||
2024 Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Convertible senior secured notes, current portion | $ 24,500,000 | $ 24,500,000 | ||||||||
2024 Notes | Convertible Senior Secured Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Exchange of notes | $ 17,200,000 | $ 305,700,000 | ||||||||
Aggregate principal amount | 305,700,000 | $ 350,000,000 | ||||||||
Stated interest rate | 2% | |||||||||
Conversion price (in dollars per share) | $ / shares | $ 29.74 | |||||||||
Threshold trading days | tradingDay | 30 | |||||||||
Number of consecutive trading days | tradingDay | 30 | |||||||||
Redemption price percentage | 100% | |||||||||
Gain (loss) on extinguishment of debt, net | $ 8,500,000 | |||||||||
Effective interest rate | 2.54% | 2.54% | ||||||||
Convertible Senior Secured Notes Due in 2028 | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Convertible senior secured notes, current portion | $ 301,100,000 | |||||||||
Convertible Senior Secured Notes Due in 2028 | Convertible Senior Secured Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Aggregate principal amount | 100,000 | $ 275,300,000 | ||||||||
Stated interest rate | 4.50% | |||||||||
Proceeds from issuance of debt | $ 30,000,000 | |||||||||
Conversion price (in dollars per share) | $ / shares | $ 2.58 | |||||||||
Convertible shares (in shares) | shares | 118,316,667 | |||||||||
Aggregate common stock converted (in shares) | shares | 141,979,975 | |||||||||
Threshold trading days | tradingDay | 60 | |||||||||
Redemption price percentage | 100% | |||||||||
Minimum revenue in last four quarters | $ 250,000,000 | |||||||||
Minimum liquidity | 15% | |||||||||
Fair value of debt instrument | $ 196,200,000 | $ 196,200,000 | $ 301,100,000 | |||||||
Debt issuance costs | $ 19,900,000 | |||||||||
Minimum percentage of principal notes outstanding for warrants to be issued | 0.10 | |||||||||
Convertible Senior Secured Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Convertible senior secured notes, current portion | $ 445,700,000 | $ 445,700,000 | ||||||||
Convertible Senior Secured Notes | Convertible Senior Secured Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Aggregate principal amount | $ 1,150,000,000 | |||||||||
Stated interest rate | 1.50% | |||||||||
Conversion price (in dollars per share) | $ / shares | $ 43.18 | |||||||||
Number of consecutive trading days | tradingDay | 30 | |||||||||
Redemption price percentage | 100% | |||||||||
Effective interest rate | 1.95% | 1.95% | ||||||||
Series A Notes | Convertible Senior Secured Notes | ||||||||||
Debt Instrument [Line Items] | ||||||||||
Aggregate principal amount | $ 100,000 | $ 275,300,000 | ||||||||
Stated interest rate | 4.50% | |||||||||
Gain (loss) on extinguishment of debt, net | $ 200,000 | |||||||||
Debt issuance costs | $ 700,000 |
Commitments and contingencies_6
Commitments and contingencies - Other commitments and contingencies (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Aug. 27, 2021 | Jun. 30, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | |
Debt Instrument [Line Items] | ||||
Royalty rate | 7% | |||
Minimum purchase | $ 11.6 | |||
Positive outcome of litigation | ||||
Debt Instrument [Line Items] | ||||
Damages | $ 4.7 | |||
Natera vs ArcherDX | ||||
Debt Instrument [Line Items] | ||||
Awarded damages | $ 19.4 | |||
Litigation expense | 19.4 | |||
Service agreements and laboratory supplies | ||||
Debt Instrument [Line Items] | ||||
Noncancelable unconditional purchase commitments | $ 16.2 |
Stockholders' equity - Schedule
Stockholders' equity - Schedule of convertible preferred and common stock (Details) - shares | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Aug. 31, 2023 | Feb. 28, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Convertible shares issued (in shares) | 15,819,604 | 14,219,859 | ||||
Common stock: | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Shares outstanding, beginning of period | 266,762,000 | 234,767,000 | 245,562,000 | 228,116,000 | ||
Convertible shares issued (in shares) | 15,820,000 | 0 | 30,040,000 | 0 | ||
Common stock issued in connection with public offering (in shares) | 50,000 | 2,429,000 | 50,000 | 2,429,000 | ||
Common stock issued on exercise of stock options, net (in shares) | 0 | 17,000 | 2,000 | 150,000 | ||
Common stock issued pursuant to vesting of RSUs (in shares) | 3,408,000 | 4,645,000 | 8,374,000 | 9,401,000 | ||
Common stock issued pursuant to employee stock purchase plan (in shares) | 0 | 0 | 1,835,000 | 1,535,000 | ||
Common stock issued pursuant to acquisitions (in shares) | 453,000 | 972,000 | 630,000 | 1,199,000 | ||
Shares outstanding, end of period | 286,493,000 | 242,830,000 | 286,493,000 | 242,830,000 |
Stockholders' equity - Addition
Stockholders' equity - Additional information (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||
Aug. 31, 2023 USD ($) shares | Feb. 28, 2023 USD ($) shares | May 30, 2021 USD ($) | Sep. 30, 2023 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) $ / shares shares | Sep. 30, 2023 USD ($) $ / shares shares | Sep. 30, 2022 USD ($) $ / shares shares | Mar. 17, 2023 shares | Dec. 31, 2022 $ / shares shares | Sep. 30, 2019 USD ($) | Aug. 31, 2017 $ / shares | |
Class of Stock [Line Items] | |||||||||||
Common stock, shares authorized (shares) | 600,000,000 | 600,000,000 | 600,000,000 | ||||||||
Common stock, par value (dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 | 20,000,000 | ||||||||
Proceeds from issuance of common stock, net | $ | $ 2,170,000 | $ 6,267,000 | |||||||||
Convertible shares issued (in shares) | 15,819,604 | 14,219,859 | |||||||||
2024 Notes | Convertible Senior Secured Notes | |||||||||||
Class of Stock [Line Items] | |||||||||||
Aggregate principal amount | $ | $ 305,700,000 | $ 350,000,000 | |||||||||
Convertible Senior Secured Notes Due in 2028 | Convertible Senior Secured Notes | |||||||||||
Class of Stock [Line Items] | |||||||||||
Aggregate principal amount | $ | $ 100,000 | 275,300,000 | |||||||||
Common stock registered (in shares) | 111,627,888 | ||||||||||
Proceeds from issuance of debt | $ | $ 30,000,000 | ||||||||||
Series A convertible preferred stock | |||||||||||
Class of Stock [Line Items] | |||||||||||
Preferred stock, conversion ratio | 1 | ||||||||||
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.0001 | ||||||||||
Liquidation preference per share (in dollars per share) | $ / shares | $ 0.001 | ||||||||||
Preferred stock, shares authorized (in shares) | 3,458,823 | 3,458,823 | 3,458,823 | ||||||||
Preferred stock, outstanding (in shares) | 0 | 0 | 0 | ||||||||
Common stock | |||||||||||
Class of Stock [Line Items] | |||||||||||
Convertible shares issued (in shares) | 15,820,000 | 0 | 30,040,000 | 0 | |||||||
2021 Sales Agreement | Cowen and Company, LLC | |||||||||||
Class of Stock [Line Items] | |||||||||||
Percentage of commission payable on gross proceeds | 3% | ||||||||||
2021 Sales Agreement | Maximum | Cowen and Company, LLC | |||||||||||
Class of Stock [Line Items] | |||||||||||
Proceeds from issuance of common stock, net | $ | $ 400,000,000 | ||||||||||
2021 Sales Agreement | Common stock | Cowen and Company, LLC | |||||||||||
Class of Stock [Line Items] | |||||||||||
Proceeds from issuance of common stock, net | $ | $ 100,000 | $ 10,000,000 | $ 100,000 | $ 10,000,000 | |||||||
Number of shares sold in underwritten public offering (in shares) | 50,400 | 2,400,000 | 50,400 | 2,400,000 | |||||||
Shares issued price per share (in dollars per share) | $ / shares | $ 1.10 | $ 3.99 | $ 1.10 | $ 3.99 | |||||||
Net proceeds from issuance of common stock | $ | $ 100,000 | $ 9,700,000 | $ 100,000 | $ 9,700,000 |
Stock incentive plans - Additio
Stock incentive plans - Additional information (Details) $ in Thousands, shares in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||
Oct. 31, 2020 shares | Sep. 30, 2023 USD ($) | Jun. 30, 2023 employees | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Apr. 30, 2021 USD ($) | |
Stock incentive plan | ||||||||
Total stock-based compensation expense | $ 25,997 | $ 60,413 | $ 85,554 | $ 164,314 | ||||
Number of employees who were granted retention-related RSUs | employees | 2 | |||||||
RSU | ||||||||
Stock incentive plan | ||||||||
Vesting period | 2 years | |||||||
Stock incentive plans | ||||||||
Stock incentive plan | ||||||||
Vesting period | 4 years | |||||||
Stock incentive plans | Stock options | ||||||||
Stock incentive plan | ||||||||
Vesting rate upon anniversaries | 25% | |||||||
Monthly vesting rate thereafter | 2.08% | |||||||
Stock incentive plans | RSU | Executive Officer | ||||||||
Stock incentive plan | ||||||||
Vesting period | 3 years | |||||||
Management Incentive Plan | PRSU | ||||||||
Stock incentive plan | ||||||||
Vesting period | 2 years | |||||||
Minimum | 2010 Plan | ||||||||
Stock incentive plan | ||||||||
Employees holding voting rights of all classes of stock | 10% | |||||||
Exercise price of options on common stock | 110% | |||||||
Maximum | 2010 Plan | ||||||||
Stock incentive plan | ||||||||
Term of options granted | 10 years | |||||||
ArcherDX | Stock incentive plans | Stock options | ||||||||
Stock incentive plan | ||||||||
Number of options issued and vested (in shares) | shares | 3.7 | |||||||
Genosity | ||||||||
Stock incentive plan | ||||||||
Total stock-based compensation expense | 400 | 400 | $ 1,200 | 1,300 | ||||
Genosity | RSU | ||||||||
Stock incentive plan | ||||||||
Business acquisition, value of units granted | $ 5,000 | |||||||
Ciitizen | ||||||||
Stock incentive plan | ||||||||
Total stock-based compensation expense | $ 15,800 | $ 22,200 | $ 46,700 | $ 72,200 | ||||
Ciitizen | RSU | ||||||||
Stock incentive plan | ||||||||
Business acquisition, value of units granted | $ 246,900 |
Stock incentive plans - Schedul
Stock incentive plans - Schedule of activity under the plans (Details) - Stock incentive plans $ / shares in Units, shares in Thousands, $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2023 USD ($) $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | |
Stock options | ||
Activity under the plan | ||
Shares available for grant, beginning balance (in shares) | 12,625 | |
Stock options outstanding, beginning balance (in shares) | 2,541 | |
Additional shares reserved (in shares) | 9,822 | |
Options granted (in shares) | (325) | |
Options cancelled (in shares) | (381) | |
Options exercised (in shares) | (2) | |
Shares available for grant, ending balance (in shares) | 7,890 | 12,625 |
Stock options outstanding, ending balance (in shares) | 2,483 | 2,541 |
Weighted-Average Exercise Price | ||
Balance at the beginning of the period (in dollars per share) | $ / shares | $ 8.49 | |
Options granted (in dollars per share) | $ / shares | 1.46 | |
Options cancelled (in dollars per share) | $ / shares | 9.25 | |
Options exercised (in dollars per share) | $ / shares | 0.86 | |
Balance at the end of the period (in dollars per share) | $ / shares | $ 7.46 | $ 8.49 |
Additional information | ||
Weighted-average remaining contractual life | 6 years 8 months 12 days | 6 years 7 months 6 days |
Aggregate Intrinsic Value | $ | $ 0 | $ 16 |
Exercisable, number of shares | 1,498 | |
Exercisable, weighted-average exercise price (in dollars per share) | $ / shares | $ 9.78 | |
Exercisable, weighted-average remaining contractual life | 5 years 2 months 12 days | |
Exercisable, aggregate intrinsic value | $ | $ 0 | |
Vested and expected to vest | ||
Number of shares | 2,335 | |
Weighted-average exercise price (in dollars per share) | $ / shares | $ 7.76 | |
Weighted-average remaining contractual life | 6 years 6 months | |
Aggregate intrinsic value | $ | $ 0 | |
RSUs and PRSUs | ||
Activity under the plan | ||
RSUs and PRSUs granted (in shares) | (17,448) | |
RSUs and PRSUs cancelled (in shares) | 2,835 |
Stock incentive plans - Summary
Stock incentive plans - Summary of RSU activity (Details) shares in Thousands | 9 Months Ended |
Sep. 30, 2023 $ / shares shares | |
RSUs and PRSUs | |
Number of Shares | |
Balance at the beginning of the period (in shares) | shares | 11,895 |
Balance at the end of the period (in shares) | shares | 18,134 |
Weighted- Average Grant Date Fair Value Per Share | |
Balance at the beginning of the period (in dollars per share) | $ / shares | $ 11.70 |
Balance at the end of the period (in dollars per share) | $ / shares | $ 1.28 |
RSU | |
Number of Shares | |
RSUs granted (in shares) | shares | 17,448 |
RSUs vested (in shares) | shares | (8,374) |
RSUs cancelled (in shares) | shares | (2,835) |
Weighted- Average Grant Date Fair Value Per Share | |
RSUs granted (in dollars per share) | $ / shares | $ 1.12 |
RSUs vested (in dollars per share) | $ / shares | 13.81 |
RSUs cancelled (in dollars per share) | $ / shares | $ 7.02 |
Stock incentive plans - Summa_2
Stock incentive plans - Summary of stock based compensation expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Stock-based compensation | ||||
Total stock-based compensation expense | $ 25,997 | $ 60,413 | $ 85,554 | $ 164,314 |
Cost of revenue | ||||
Stock-based compensation | ||||
Total stock-based compensation expense | 755 | 1,203 | 2,791 | 5,702 |
Research and development | ||||
Stock-based compensation | ||||
Total stock-based compensation expense | 19,081 | 24,301 | 58,800 | 94,661 |
Selling and marketing | ||||
Stock-based compensation | ||||
Total stock-based compensation expense | 1,354 | 2,625 | 6,245 | 10,498 |
General and administrative | ||||
Stock-based compensation | ||||
Total stock-based compensation expense | 4,755 | 7,477 | 17,661 | 28,646 |
Restructuring, impairment and other costs | ||||
Stock-based compensation | ||||
Total stock-based compensation expense | $ 52 | $ 24,807 | $ 57 | $ 24,807 |
Restructuring, impairment and_3
Restructuring, impairment and other costs - Additional Information (Details) employee in Thousands, $ in Millions | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2023 USD ($) | Sep. 30, 2022 employee | Sep. 30, 2023 USD ($) | |
Restructuring and Related Activities [Abstract] | |||
Reduction of employees | employee | 1 | ||
Gain on extinguishment of contractual liability | $ | $ 5.5 | $ 5.5 |
Restructuring, impairment and_4
Restructuring, impairment and other costs - Restructuring Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Restructuring and Related Activities [Abstract] | ||||
Employee severance and benefits | $ 1,022 | $ 57,903 | $ 2,285 | $ 57,903 |
Impairments and losses on disposals of long-lived assets, net | 881,165 | 55,500 | 1,012,360 | 60,317 |
Other restructuring costs | (4,898) | 11,819 | (3,802) | 11,819 |
Total restructuring, impairment and other costs | $ 877,289 | $ 125,222 | $ 1,010,843 | $ 130,039 |
Restructuring, impairment and_5
Restructuring, impairment and other costs - Changes In Liabilities (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2023 | Dec. 31, 2022 | |
Restructuring Reserve [Roll Forward] | ||
Restructuring reserve, beginning balance | $ 4,204 | $ 0 |
Accruals | 4,094 | 42,642 |
Payments | (6,326) | (38,438) |
Restructuring reserve, ending balance | 1,972 | 4,204 |
Employee severance and benefits | ||
Restructuring Reserve [Roll Forward] | ||
Restructuring reserve, beginning balance | 2,263 | 0 |
Accruals | 2,228 | 35,237 |
Payments | (3,316) | (32,974) |
Restructuring reserve, ending balance | 1,175 | 2,263 |
Other restructuring costs | ||
Restructuring Reserve [Roll Forward] | ||
Restructuring reserve, beginning balance | 1,941 | 0 |
Accruals | 1,866 | 7,405 |
Payments | (3,010) | (5,464) |
Restructuring reserve, ending balance | $ 797 | $ 1,941 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | ||||
Income tax benefit | $ 6,171 | $ 1,068 | $ 8,055 | $ 39,551 |
Income tax benefit, amortization and impairment of foreign acquired intangibles | 6,500 | |||
Release of federal and state valuation allowances | 1,600 | |||
Unrecognized tax benefits | 59,300 | 59,300 | ||
Unrecognized tax benefits, portion that would affect tax rate | $ 200 | $ 200 |
Net loss per share - Schedule o
Net loss per share - Schedule of earnings per share, basic and diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Earnings Per Share [Abstract] | |||||||
Net loss | $ (942,107) | $ (301,156) | $ (1,340,801) | $ (3,006,476) | $ (3,100,000) | $ (379,000) | $ (602,200) |
Shares used in computing net loss per share, basic | 275,604 | 237,974 | 263,210 | 232,889 | |||
Shares used in computing net loss per share, diluted | 275,604 | 237,974 | 263,210 | 232,889 | |||
Net (loss) income per share, basic (in dollars per share) | $ (3.42) | $ (1.27) | $ (5.09) | $ (12.91) | |||
Net (loss) income per share, diluted (in dollars per share) | $ (3.42) | $ (1.27) | $ (5.09) | $ (12.91) |
Net loss per share - Schedule_2
Net loss per share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares shares in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Net loss per common share | ||||
Total shares of common stock equivalents (in shares) | 168,453 | 62,284 | 139,491 | 62,456 |
Shares of common stock subject to outstanding options | ||||
Net loss per common share | ||||
Total shares of common stock equivalents (in shares) | 2,503 | 3,621 | 2,456 | 3,174 |
Shares of common stock subject to outstanding RSUs and PRSUs | ||||
Net loss per common share | ||||
Total shares of common stock equivalents (in shares) | 16,637 | 18,660 | 15,749 | 18,587 |
Shares of common stock pursuant to ESPP | ||||
Net loss per common share | ||||
Total shares of common stock equivalents (in shares) | 3,436 | 1,600 | 3,580 | 2,292 |
Shares of common stock subject to convertible senior notes conversion | 2024 Notes | ||||
Net loss per common share | ||||
Total shares of common stock equivalents (in shares) | 27,543 | 38,403 | 27,543 | 38,403 |
Shares of common stock subject to convertible senior notes conversion | Convertible Senior Secured Notes Due in 2028 | ||||
Net loss per common share | ||||
Total shares of common stock equivalents (in shares) | 118,334 | 0 | 90,163 | 0 |
Geographic information - Schedu
Geographic information - Schedule of revenue by country (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Geographic information | ||||
Total revenue | $ 121,241 | $ 133,536 | $ 359,129 | $ 393,849 |
United States | ||||
Geographic information | ||||
Total revenue | 113,723 | 117,316 | 337,457 | 345,721 |
Canada | ||||
Geographic information | ||||
Total revenue | 1,886 | 2,099 | 6,276 | 6,567 |
United Kingdom | ||||
Geographic information | ||||
Total revenue | 1,401 | 3,004 | 3,235 | 7,872 |
Rest of world | ||||
Geographic information | ||||
Total revenue | $ 4,231 | $ 11,117 | $ 12,161 | $ 33,689 |